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 The development of effective antiretroviral medications transformed treatment for 
individuals living with HIV. Strict adherence to medical regimens is essential for ideal 
treatment of patients living with HIV, yet significant barriers result in most patients 
failing to achieve adequate adherence (Chesney et al., 2000; Friedland, 2006). 
Nonadherence to prescribed antiretroviral medications may result in failure to achieve 
viral suppression and increased HIV replication and may lead to the development and 
transmission of drug resistant strains of HIV. Consequently, health care providers 
increasingly are offering patients assistance with medication adherence to reduce the 
chances of treatment failure and to decrease development of drug resistant strains being 
transmitted to the public (Smith, Golin, & Reif, 2004).  
 Currently, HIV medication regimens are individually tailored to the patient, 
therefore the number of pills and how often the patient is required to take the medication 
varies. Most regimens require multiple pills throughout the day, some of which must be 






doses of other medications. This complex regimen poses multiple barriers to adherence 






 Additionally, numerous biological, behavioral, and social factors influence 
medication adherence. The most commonly reported deterrents of adherence among patients 
are adverse side effects of the regimen, large numbers of pills, and dosing restrictions (i.e., 
frequency and requirement of food or water). Behavioral factors, which often lie at the root 
of treatment failure, include accurate knowledge regarding the regimen, cognitive 
functioning (i.e., remembering the regimen and having the capacity to understand dosing 
requirements), motivation, and skills (Friedland, 2006). Many patients report forgetting to 
take the medications, especially when they are not at home; being uncertain about how to 
take the medications; and believing that they cannot adhere to the strict regimen requirements 
(Roberts, 2000)(K. J. Roberts, 2000). Implementing the medication regimen into daily life 
and being unable to take medications privately while at work or in public pose a significant 
barrier to patients. It is imperative that health care providers address these issues with 
patients, particularly with newly diagnosed patients, those beginning a new regimen, and 
those who are identified as nonadherent.  
 Health care providers have implemented a variety of behavioral interventions 
designed to promote adherence to medication regimens. Many of these interventions are 
multi-component and consist of memory-prompting devices (i.e., medication cards, 
pillboxes), increased social support, and motivational strategies. In a review of 88 descriptive 
and intervention studies, Sandelowski and colleagues (2009) found that cognitive behavioral 
interventions were most prevalently used to address problems with medication adherence. 
These interventions were directed toward knowledge, beliefs about HIV infection and 






demonstrated that medication adherence is not a static, one-dimensional behavior; rather, 
multiple emotional, cognitive, and behavioral factors that frequently change influence 
adherence (Johnson, et al., 2003, Remien, Hirky, Johnson, Weinhardt, Whittier, & Le, 2003; 
Sandelowski, Voils, Chang, & Lee, 2009). Thus, effective interventions should target each of 
these factors, including components of education, skill-building, motivation enhancement, 
and problem-solving techniques (Johnson et al., 2003). 
 The Life Steps program is a brief adherence intervention that combines components 
from several empirically validated intervention approaches, including both Brief 
Motivational Interviewing (BMI) and Cognitive Behavior Therapy (CBT), which has been 
effective in increasing medication adherence among patients with HIV. Safren and 
colleagues developed the Life Steps program based on principles of CBT, BMI, and problem-
solving therapy to help patients identify and solve problems with medication adherence 
(Safren et al., 2001). This brief, single-session intervention is designed to provide patients 
with education and training in medication adherence. Safren and colleagues (2001) compared 
the Life Steps program to self-monitoring of medication adherence, which has also been 
supported in the empirical literature. Results demonstrated improvements in adherence in 
both conditions at two weeks posttreatment and 12-weeks posttreatment; however, the Life 
Steps condition showed faster improvements in adherence rates than the self-monitoring 
condition. This suggests that the inclusion of problem-solving and motivational interventions 







While the evidence for Life Steps is promising, the dissemination and adoption of the 
program is limited by several practical barriers, including the expense of professional staff, 
training needs, time demands upon staff in the clinical environment, and concerns about 
treatment fidelity. The development of a brief, computerized intervention adapting the 
components of Life Steps and targeting medication adherence may reduce the already 
demanding time constraints placed on physicians and health care providers. Further, this 
intervention will be economically feasible, cost-effective, and easily disseminated among 
patients who are at-risk for nonadherence, particularly patients who are initiating treatment, 
changing regimens, or have demonstrated previous failures to adhere to the regimen. This 
program could be delivered via local computer or tablet device and included on a compact 
disc or made available via the internet, allowing easy access to developing skills for 
adherence and periodic review of procedures for patients outside of the clinical setting. An 
electronic computer-based intervention would provide a standardized method intervention 
which would greatly assist health care providers who currently have limited time constraints 
and resources to provide such an intervention.  
The purpose of the current study was to develop and test a multimedia electronic 
intervention (Electronic Life Steps, or eLS) for improving adherence to antiretroviral therapy 
treatments among patients living with HIV.  We hypothesized that individuals who 
completed the eLS intervention would (1) report high satisfaction with the computer-based 
program; (2) demonstrate higher self-efficacy to adhere to their prescribed antiretroviral 











This study was conducted in an outpatient community health center in Tulsa, OK 
which primarily serves persons infected with HIV. This study was approved by the 
Institutional Review Board. Voluntary, written informed consent was obtained from all 
participants. The trial was registered at clinicaltrials.gov (NCT01291485). Full details of 
the trial protocol can be found in Appendix D and available at www.who.int/ictrp/en. 
Participants 
Participants were recruited for this study from an outpatient clinic that serves 
primarily patients living with HIV.  Patients were eligible for enrollment in the trial if 
they met the following inclusion criteria (a) infected with HIV, (b) at least 18 years of 
age, (c) currently prescribed a Highly Active Antiretroviral Therapy (HAART) regimen, 
(d) prescribed a drug regimen for the first time, were changing regimens, or reported 
adherence below 95%, and (e) agreed to a brief follow-up interview. Participants were 
excluded from the study if they presented with a physical impairment that would prevent 






neurpsychological impairment), reported being actively psychotic, or were not fluent in 






assigned to one of the following conditions: (1) Treatment as usual (TAU; N = 50) or (2) 
TAU + Electronic Life Steps intervention (N = 47).  Blocked randomization was used to 
ensure close balance of the numbers in each group throughout the trial. For every block 
of 10 participants, five were allocated to each arm of the trial. 
Design and Procedures 
After providing written consent to participate in the study, all participants 
completed a brief questionnaire which assessed demographic information, adherence to 
HIV medications (AACTG Medication Adherence Questionnaire), and confidence and 
commitment to adhere to the prescribed HIV regimen.  
Intervention Condition 
 The Electronic Life Steps (eLS) experimental intervention was developed on the 
basis of prior studies of interventions designed to improve HIV medication adherence and 
was based on components of brief motivational interviewing, cognitive behavioral 
therapy, and problem solving training (Safren, Otto, & Worth, 1999). The intervention 
was delivered in a single-session format. Completion of the intervention varied by 
participant and ranged from 33 minutes to approximately 90 minutes. The program 
features an audio interviewer that guides the user through the program, video examples, 
and problem-solving modules that encourage the user to engage in personalized reflection 
and planning. The program utilizes an accompanying workbook with a number of 
worksheets that the user is encouraged to complete while progressing through the 






Consistent with the original Life Steps intervention, the assessment intervention 
itself included 10 informational, problem-solving, and cognitive behavioral steps, each 
presented as a separate module (see Table 1 for module descriptions). Completion of one 
module directs the participant directly to the subsequent module. After the intervention, 
participants completed several additional questionnaires designed to assess self-efficacy 
to adhere to HIV regimen (HIV Treatment Adherence Self-Efficacy Scale), readiness to 
adhere to the treatment regimen (HIV Medication Readiness Scale), quality of life 
(McGill Quality of Life Questionnaire), and intervention satisfaction (The Program 
Satisfaction Questionnaire).  Participants in the TAU condition completed these 
measures with the demographics and adherence measures at baseline. Participants were 
entered into a drawing to win a portable DVD player at completion of the baseline 
assessment. Each participant received $5 upon completion of the follow-up assessment 
interview which was scheduled at 1-month for both the intervention and control groups. 
Measures 
 Demographics Questionnaire. Basic demographic data was collected including 
information regarding gender, age, ethnicity, current living situation, marital status, 
sexual orientation, educational attainment and treatment history. 
 Medication Adherence. Self-reported adherence to HIV medications was assessed 
using the AACTG Medication Adherence Questionnaire (Chesney et al., 2000). This 
measure queries patients on the number of doses missed of each medication during each 
of the last four days.  Additionally, other adherence behaviors are assessed such as 






patient followed the specific schedule.  Adherence was calculated by averaging the total 
number of pills taken over 4 days divided by the total number of pills prescribed. Scores 
range from 0-100%, with higher scores indicating a greater level of adherence.  
 HIV Treatment Adherence Self-Efficacy. Self-efficacy for adherence to HIV 
medications was assessed using the HIV Treatment Adherence Self-Efficacy Scale (HIV-
ASES; Johnson, Neilands, Dilworth, Morin, Remien, & Chesney, 2007).  The HIV-ASES 
is a 12-item scale of patient confidence in their ability to carry out behaviors related to 
adhering to medication regimens.  Responses range from 1 (“cannot do it at all”) to 10 
(“completely certain can do it”).  Item scores are averaged with higher scores indicating 
higher adherence self-efficacy.  Analysis of the HIV-ASES has revealed robust internal 
consistency (.90) and reliability (.91). 
 Commitment to Adhere to HIV Medication Regimens. This item was developed 
for the purposes of this study and consists of a single question addressing the 
participant’s level of commitment to adhere to the currently prescribed antiretroviral 
medication regimen. Responses range from 0 (“not committed at all”) to 10 (“completely 
committed”) with high scores demonstrating higher levels of commitment to adherence. 
Clinical outcomes. Medical records for each subject were reviewed for the most 
recent laboratory test results of CD4+ cell counts and viral load.  These records were 
reviewed four weeks after baseline assessment and within two weeks after each follow-up 
point. This time frame allowed the investigators to access the most recent clinical data 






 Program Satisfaction Questionnaire. This questionnaire was developed for the 
purposes of this study to address the level of satisfaction with the intervention.  This 
questionnaire consists of eight items assessing level of agreement or disagreement with 
the statement, such as “I would recommend this program to a friend” and “I learned new 












Table 2 provides details of the participant characteristics for each randomization 
group. The sample was predominantly male, with 59% identifying as White, 21% as 
African-American, and 11% as American Indian. The mean age was 44 years. The 
sample was balanced across randomization conditions with regard to all demographic 
variables. 
Assessment and Intervention Completion Rates 
Of the 97 individuals enrolled in the trial and randomized, 71% completed the 1-
month follow-up assessment. Of the 47 individuals randomized to the intervention 
condition, 43 (93.5%) completed the first session and 32 (74.4%) completed the 1-month 
follow-up. See Figure 1 for the clinical trial participant flow details. Attrition rates across 
the two conditions were not different χ
2
(1, 97) = 0.79, p = .375. The attrition rate between 
baseline assessment and 1-month follow-up was 25%. Reasons for attrition are as 
follows: (1) death (N = 1); (2) hospitalization (N = 1); and (3) unable to be contacted via 






Attrition is a common challenge to HIV clinical trials.  Amico, Harman, & 
O’Grady (2009) reviewed 51 studies and found that the mean attrition rate was 30% for 
the study sample of HIV intervention trials with some studies reporting attrition rates as 
high as 60-77%. The attrition rate within this study falls within the expected range for 
HIV clinical trials. High levels of attrition can bias results and present threats to validity; 
however, this is only problematic if there are systematic differences between participants 
who completed the study and those who dropped out (Hansen, Collins, Malotte, Johnson, 
& Fielding, 1985 as cited in Grant, Beck, Farrow, & Davila, 2007). To examine this 
possibility t-tests and chi-square tests were conducted between participants who 
completed the study and those who dropped out prematurely on demographic variables 
and variables used in the main analyses. No significant differences were found between 
groups on either demographic variables or variables used in the primary analyses (see 
Table 4). Consequently, the effect of attrition on study conclusions should be minimal.  
For participants with missing data, regression mean imputation was used to calculate the 
predicted missing variables which were then substituted for each unit with a missing 
value. Additionally, analyses were examined excluding participants who did not complete 
the study (see Appendix E for additional analyses).  
Randomization check and preliminary analysis 
Chi-square analyses were conducted to test for any significant condition 
differences with regard to gender, ethnicity, education, marital status, and sexual 
orientation across conditions, with no significant differences found (all p>.05). A t-test 








 cell count (p<.01) and viral load (p>.05), revealing a significant difference 
between groups on CD4
+
 cell count. Specifically, participants in the intervention 
condition demonstrated significantly lower CD4
+
 counts (M = 486, SD = 224.84) 
compared to the TAU condition (M = 1936.84, SD = 3336.97).   
Patient Satisfaction with the Intervention 
 Means and standard deviations for the participant satisfaction measure were 
evaluated and compared to the scale anchors to determine if the level of satisfaction with 
the Electronic Life Steps program was relatively high or low. Of the 47 participants in the 
intervention condition, 85.1% agreed or strongly agreed that they were satisfied with the 
program and 76.6% reported learning new things from the intervention. Additionally, 
80.9% reported that the intervention made them think about their adherence to HIV 
medications.       
Primary Analyses 
 Between-group differences were evaluated with t-tests of group means. A series 
of repeated measures ANOVA tests were conducted with condition (eLifeSteps and 
Treatment as Usual) as the between-subjects factor and time (baseline and 1-month 
follow-up) as the within-subjects factor. Dependent variables included self-efficacy, 
adherence, CD4+ count, and viral load. See Table 3 for baseline and follow-up means 
and standard deviations for the dependent variables. 
Treatment Self-Efficacy 
Immediate post-intervention scores on the measure of self-efficacy (HIV-ASES) 






used to predict self-efficacy scores for participants who were missing data points at one-
month follow-up.  First, means and regression coefficients were calculated at baseline 
and included in the regression equation for each condition.  Second, the predicted score 
was calculated and imputed for each participant with missing data at 1-month follow-up.  
Time  Condition interaction effects in mixed model ANOVAs were examined and 
demonstrated a significant difference between the two conditions F(1, 87) = 4.70, p = .03, 

2
=.05. Between-group differences in self-efficacy were evaluated at the baseline and 
one-month follow-up time point with t-tests of group means. Results failed to reach 
significance at baseline t(87) = 1.48, p = .14; however, there was a significant difference 
in treatment self-efficacy between conditions at 1-month follow- up, t(89) = 2.50, p = .01, 
with participants in the eLifeSteps condition reporting higher scores of self-efficacy to 
adhere to their HIV treatment regimen (M =8.77, SD = 1.34)  compared to the TAU 
participants (M =7.96, SD = 1.67).   
Adherence 
Adherence scores were calculated for all participants using self-reported 4-day 
recall data. For those who were missing data points, regression imputation was used to 
predict scores for that participant’s 1-month follow-up data point. Time  Condition 
interaction effects in mixed model ANOVAs were also evaluated to examine differences 
in patterns of change in adherence over time between the two groups.  Although 
approaching significance, the interaction term failed to demonstrate a statistically 
significant difference in the pattern of change in adherence over time, F(1, 92) = 3.75, 
p=.056, 
2






1-month follow-up with t-tests of group means. There was a significant difference in 
adherence levels between the two conditions at baseline, t(92) = -2.16, p = .03, with the 
TAU group (M = 80.81, SD = 26.41) reporting significantly greater levels of adherence 
than the eLifeSteps group (M = 67.20, SD = 34.29). Results from the t-test at one-month 
follow-up failed to demonstrate a significant difference between conditions, t(93) = -0.10, 
p = .92. These results demonstrated a trend in improved adherence over time among 
participants in the eLifeSteps condition, while participants in the TAU condition remained 
consistent between baseline and follow-up (see Figure 2 for change in adherence by 
condition at baseline and follow-up.) 
Clinical Outcomes 
Differences in viral load and CD4+ cell counts were examined by extracting data 
from medical records beginning with examining the most recent clinical outcome data at 
baseline assessment and examining data three months post-baseline assessment. Data 
points were available and extracted for 85 participants. Last observation carried forward 
(LOCF) was used to complete the missing data points from baseline to three month 
follow-up. Between-group differences in CD4+ count and viral load were evaluated at 3-
month follow-up with t-tests of group means, with no significant differences (all p>.05).  
See Table 5 for means and standard deviations of clinical outcome data.  
Time (Post-intervention and 3-month follow-up)  Treatment (TAU, eLifeSteps) 
interaction effects in mixed model ANOVAs were also evaluated to examine differences 
in patterns of change in viral and immunologic outcomes over time between the two 








results for viral load also were nonsignifcant, F(1, 83) = 1.96, p=.17, 
2
=.02; however, it 
should be noted that a trend was observed in which participants in the eLifeSteps group 
demonstrated a decrease in viral load from baseline (M = 19959.07, SD = 89499.42) to 
follow-up (M = 4425.12, SD = 21888.61) and an increase in viral load for participants in 
the TAU group from baseline (M = 3316.19, SD = 17267.31) to follow-up (M = 7711.16, 












Nonadherence to prescribed medication regimens among HIV patients is a serious 
public health concern.  Widespread dissemination of current efficacious interventions 
designed to improve adherence is limited by several practical barriers including 
additional time and expense burdens in the health care systems. Electronic interventions 
could overcome these barriers and aid dissemination of an efficacious intervention in the 
clinic setting. This study provides support that a computer-based HIV adherence 
intervention is feasible and easily implemented into a busy outpatient medical setting. 
Participant satisfaction data strongly support the relevance and helpfulness of the 
program among patients living with HIV. Eighty-five percent of the participants reported 
being satisfied with the program and approximately 81% indicated that the computer-
based intervention made them think about their adherence to their HIV medication 
regimen. 
Additionally, these results demonstrated that participants in the eLifeSteps 






month follow-up compared to the TAU condition. Although levels of adherence were 






condition demonstrated an increase in self-reported medication adherence at 1-month 
follow-up and participants in the TAU condition remained constant. Finally, this study 
was underpowered to detect significant differences in viral and immunological outcomes. 
However, it should be noted that trends in the 3-month assessment of CD4 and viral load 
revealed that participants in the eLifeSteps condition reported an improvement in clinical 
outcomes; whereas, participants in the TAU condition declined. 
Several limitations to this study need to be acknowledged. First, this is the initial 
empirical demonstration of the eLifeSteps intervention; therefore replication and 
extension are required. Second, the relatively short 1-month follow-up period 
demonstrated improvements in self-efficacy and adherence; however, additional 
longitudinal follow-up data is needed to determine the length of effects of such an 
intervention. Third, this study relied on self-reported adherence as the main outcome. 
Although there is currently no gold standard for assessing medication adherence and the 
current literature supports the use of the ACTG 4-day recall measure (Chesney et al., 
2000), the use of more objective measures of adherence may provide a more valid 
measurement of adherence. Finally, the intervention sample in this study demonstrated 
significant differences in baseline CD4 count and levels of adherence with participants in 
the eLifeSteps intervention reporting lower CD4 counts and lower levels of adherence 
compared to the TAU condition. This suggests that the intervention condition was, 
overall, more at-risk for nonadherence compared to the TAU condition. Additionally, 
data for this study was gathered at a federally funded outpatient clinic that primarily 






The present study is the first to examine a computer-based intervention to 
promote HIV adherence delivered via a single-session format. The authors identified only 
one other study that developed and tested the efficacy of a computer-based HIV 
adherence promotion intervention. Fisher and colleagues (2011) developed a similar 
intervention that was administered at each of the participant’s regularly scheduled HIV 
care visits over approximately 18 months. This study found that participants who used the 
computer-based intervention consistently for at least six times demonstrated higher levels 
of perfect adherence over time; whereas, the control group exhibited a decline in 
adherence over time.  This may indicate that, to achieve statistically significant 
differences in adherence between the intervention and control groups, multiple 
administrations of the intervention are required compared to the single-session format 
presented in this paper. 
 Unfortunately, implementation of a multi-session program may increase burdens 
for clinic staff to identify which modules patients need to complete at each visit. The 
eLifeSteps intervention presented in this paper is designed to be completed at only one 
clinic visit among patients identified as at-risk for nonadherence (e.g., patients newly 
prescribed a antiretroviral regimen, changing regimens, or report adherence <90%). 
Participants in this study received a copy of the program on compact disc and were given 
their user-journal to review the steps when needed. It is important for future studies to 
examine this single-session format compared to multi-session formats of computer-based 






The use of technology-assisted interventions is a convenient, economical solution 
to the current limitations imposed upon health care providers.  This type of intervention 
requires minimum training and time by clinic staff and can be implemented in clinic 
waiting rooms.  Additionally, this technology has the potential to be used in rural settings 
that lack access to psychological interventions and may be adapted to be used with a wide 
array of chronic illnesses requiring stringent medication adherence.  Developing 
electronic interventions based on currently existing empirically supported interventions 
may help alleviate the gap between patient nonadherence and the barriers that limit 
practitioners from delivering comprehensive, multifaceted effective interventions aimed 
at increasing adherence.  Adapting efficacious programs for HIV medication adherence, 








Table 1 eLifeSteps Intervention Modules 
Module Description 
Step 1: Education & Introduction Information about the role medication adherence plays in successful treatment is provided. The aim is 
to increase knowledge and self-efficacy to influence treatment success and introduce problem-solving 
for medication adherence. 
Step 2: Transportation to 
Appointments  
Problem-solving strategies, brief cognitive restructuring, and rehearsal techniques are provided to 
address transportation issues to prevent missed appointments with health care providers 
Step 3: Obtaining Medications Patients develop a plan for continued access to medications. Concerns regarding patient’s privacy and 
confidentiality during interactions with the pharmacist are addressed. 
Step 4: Communicating with 
Health Care Providers  
Brief cognitive techniques are suggested for irrational fears about asking questions. 
Step 5: Coping with Side-Effects In this module patients are asked to (a) help themselves pick a regimen collaboratively with their doctor 
to minimize side effects; (b) re-interpret the initial side effects as signs that the medications are in their 
bloodstream and working; and (c) increase the salience of the reasons for taking medications despite 
the side effects. 
Step 6: Formulating a Daily 
Medication Schedule 
Patients complete a detailed map of an average day of pill-taking, specifying environmental and other 
cues for pill-taking throughout the day. 
Step 7: Storing Medications Problem-solving techniques are presented to address storing medications when patients are not at 
home.  
Step 8: Cues for Pill-Taking The patient is provided with a set of colored adhesive dots which are used to cue pill taking by placing 
the dots in various spots where the patient will see them. Adaptive cognitions for adherence are 
rehearsed and overt reminders (e.g., setting alarms) for adherence are discussed. 
Step 9: Response to Slips in 
Adherence 
Patients are taught how to handle slips and to avoid all-or-nothing thoughts. Cognitive techniques to 
cope with a lapse are discussed. 
Step 10: Review This module reviews the previous steps via an imbedded quiz and provides patients feedback regarding 






Table 2 Sample characteristics
a 
 Control (N=50) Intervention (N=47) Total (N=97) 
Age (years)  42 (9.47) 43.7 (10.19) 44 (9.82) 
Gender     
     Male 42 (84%) 38 (80.9%) 80 (82.5%) 
     Female 7 (14%) 9 (19.1%) 16 (16.5%) 
Race/ethnicity     
     African-American 10 (20%) 11 (23.4%) 21 (21.6%) 
     American Indian 7 (14%) 5 (10.6%) 12 (12.4%) 
     Caucasian 29 (58%) 29 (61.7%) 58 (59.8%) 
     Other 2 (4%) 2 (4.2%) 4 (4.1%) 
Sexual orientation    
     Bisexual 2 (4%) 5 (11.6%) 7 (7.3%) 
     Heterosexual 15 (30%) 15 (34.9%) 30 (31.3%) 
     Homosexual 29 (58%) 20 (46.5%) 49 (51%) 
Education    
     Graduated High School 11 (22%) 14 (29.8%) 25 (25.8%) 
     Some College 23 (46%) 20 (42.6%) 43 (44.3%) 
     Graduated College 9 (18%) 7 (14.9%) 16 (16.5%) 
     Other 6 (12%) 6 (12.7%) 12 (12.3%) 
Means of HIV Transmission    
     Sex with a HIV+ man 34 (68%) 34 (72.3%) 68 (70.1%) 
     Sex with a HIV+ woman 5 (10%) 8 (17%) 13 (13.4%) 
     Shared needles 3 (6%) 5 (10.6%) 8 (8.2%) 
     Blood transfusion 4 (8%) 2 (4.3%) 6 (6.2%) 
     Does not know 3 (6%) 2 (4.3%) 5 (5.2%) 
Baseline adherence
b
     
     100% adherence 24 (48%) 17 (36.2%) 41 (42.3%) 
     ≥90% adherence  1 (2%) 0 (0%) 1 (1%) 
     ≥75% adherence 13 (26%) 12 (25.5%) 25 (25.7%) 
     <75% adherence 9 (18%) 18 (38.3%) 27 (27.7%) 
Follow-up adherence
b 
(1 mos)  
   
     100% adherence 22 (44%) 19 (40.4%) 41 (42.3%) 
     ≥90% adherence  0 (0%) 6 (12.8%) 6 (6.2%) 
     ≥75% adherence 17 (34%) 10 (21.3%) 27 (27.9%) 
     <75% adherence 9 (18%) 12 (25.7%) 21 (21.6%) 
a 
Data are means (SD) or numbers (%) 
b 








Treatment outcome as a function of group 
 Baseline Follow-up 
Outcome measure and group M (SD) M (SD) 
Treatment self-efficacy   
     eLifeSteps 8.46 (1.77) 8.79 (1.34) 
     TAU 7.88 (1.90) 7.98 (1.67) 
Adherence (%)   
     eLifeSteps 67.20 (34.29) 80.53 (26.29) 
     TAU 80.81 (26.41) 81.40 (25.21) 
CD4+ count   
     eLifeSteps 486 (224.84) 507.51 (242.08) 
     TAU 593.14 (299.29) 638.77 (499.64) 
Viral Load   
     eLifeSteps 19959.07 (89499.42) 4425.12 (21888.61) 








Comparison of completers and drop-outs on demographic variables and self-report measures 
Variables 
Completers (N = 74) Drop-outs (N = 23)  
M SD M SD t/χ
2 
p 
Sex     0.19 .66 
     Male (%) 82.4  86.4    
Age 42.46 9.98 44.23 9.38 31.83 .62 
Ethnicity (%)     6.48 .17 
     Caucasian 64.9  43.5    
     African-American 21.6  21.7    
     American Indian 8.1  26.1    
     Other 4.1  4.3    
Education (%)     6.95 .33 
     Graduated High School 25.7  26.1    
     Some College 47.3  34.8    
     Graduated College 17.6  13    
     Other 9.6  21.7    
Housing Status (%)     4.85 .44 
     Your house/apt 56.8  56.5    
     Someone else’s house/apt 35.1  26.1    
     Institution <30 days 1.4  0    
     Transitional Housing 5.4  4.3    
     Other 1.4  8.6    
Sexual Orientation (%)     1.12 .77 
     Bisexual 8.1  4.3    
     Gay 51.4  60.9    
     Heterosexual 33.8  26.1    
     Prefer not to respond 6.8  4.3    
CD4 cell count 555.7 263.49 460.73 285.09 -1.49 .14 
Viral load 11491.93 68073.16 6400.57 28002.00 .13 .90 













Clinical outcome data as a function of group 
Clinical outcome 
measure and group 
eLifeSteps TAU 
t p M SD M SD 
CD4+ cell count       
     Baseline 486 224.84 593.14 299.29 -1.87 .07 
     3 Month follow-up 507.51 242.08 638.77 499.64 -1.55 .12 
Viral Load       
     Baseline 19959.07 89499.42 638.77 499.64 1.18 .24 
















Assessed for Eligibility (n=441) 
Excluded (n=344) 
     Not Meeting Inclusion Criteria (n=222) 
     Declined to participate (n=122) 
 
Allocated to Intervention (n=47) 
     Received allocated intervention (n=43) 
     Did not receive allocated intervention      
    (e.g., adverse event, limited time) (n=4) 
 
Allocated to Treatment As Usual (n=50) 
     Received allocated intervention (n=49) 
     Did not receive allocated intervention      
    (e.g., withdrew after consent) (n=1) 
 
Completed 1 month Follow-up (n=32) 
Lost to follow-up (phone disconnected,  
     unable to be reached) (n=11) 
Completed 1 month Follow-up (n=37) 
Lost to Follow-up (phone disconnected, 
     unable to be reached, hospitalization,  
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Epidemiology of Adherence to HIV Medications 
Nonadherence to prescribed medication regimens among HIV patients is a serious public 
health concern.  Unlike most other chronic illnesses, effective HIV treatment requires a stringent 
adherence rate of 95% or better to maximize the chances of treatment success and improve 
clinical outcomes.  Rates of non-adherence range from 31-70% among patients with HIV and 
tend to decline over time (Ickovics et al., 2002; Johnson, et al., 2003; Paterson et al., 2000).  
Consistent, long-term adherence is essential for optimal clinical outcomes and improved quality 
of life (H. Wang et al., 2009).  Individuals with inadequate adherence are at risk for disease 
progression, development of drug resistance, and mortality.  More specifically, people with HIV 
who adhere to their regimens 70-90% of the time present the greatest risk for virological failure, 
immunologic failure, and development of treatment resistant strains of HIV (Lucas, 2005).   
Drug resistance is a major concern for patients currently taking HIV medications due to 
the possibility of developing a superinfection which is a result of being infected with multiple 
strains of the virus, some of which may be treatment resistant.  Additionally, treatment resistance 
is a concern for patients who are newly infected with the virus and for those who are initiating 
medication treatment (Klimas, Koneru, & Fletcher, 2008).  The presence of drug resistant 
mutations presents a serious public health concern in the prevention and control of HIV.  
Transmission of drug resistant strains leaves patients with minimal treatment options once the 
virus progresses to a stage in which treatment is warranted.  These patients may continue anti-
HIV medication therapy and receive some clinical benefits; however, the virus will likely 






treatment resistant strains of the virus, a 95% or greater rate of adherence to HIV medication 
regimens is necessary. 
 Unfortunately, multiple factors pose significant problems to maintaining a very high rate 
of adherence long-term.  The medication regimens are complex and often result in many side 
effects (Paterson, et al., 2000).  Highly Active Antiretroviral Therapy (HAART) is the 
recommended treatment for HIV and requires a combination of drugs belonging to two classes of 
antiretroviral agents (Klimas, et al., 2008).  Medication regimens are individually tailored to the 
patient, therefore the number of pills and how often the patient is required to take the medication 
varies.  Most regimens require multiple pills throughout the day in which some must be taken on 
an empty stomach, while others must be taken with meals or before or after doses of other 
medications.  This complex regimen poses multiple barriers to adherence and many challenges 
for people taking antiretroviral medications. 
 In addition to the complex regimen, numerous biological, behavioral, and social factors 
influence medication adherence. Biological factors include disease status, host immunology, 
genetics, and characteristics of the medications, including drug potency and pharmacology 
(Friedland, 2006). The most reported deterrents of adherence among patients is adverse side 
effects of the regimen, the large number of pills, and dosing restrictions (i.e., frequency and if 
they require food or water). Behavioral factors, which often lie at the root of treatment failure, 
include accurate knowledge regarding the regimen, cognitive functioning (i.e., remembering the 
regimen and having the capacity to understand dosing requirements), motivation, and skills 
(Friedland, 2006).  Many patients report failing to remember to take the medications, especially 






they cannot adhere to the strict regimen requirements (Kathleen Johnston Roberts, 2000). Social 
factors such as availability of resources, access to care and treatment, race, gender, and stigma 
play an important role in adherence as well (Friedland, 2006). Implementing the medication 
regimen into daily life and being unable to take medications privately while at work or in public 
pose a significant barrier to patients. It is imperative that health care providers address these 
issues with patients, particularly those beginning a new regimen or who are nonadherent.   
 Medication adherence has been a primary concern among health care providers since the 
inception of antiretroviral medications. Due to the strict adherence rate, the proportion of 
individuals with HIV who maintain optimal level of adherence is relatively small. Multiple 
studies have found that as many as 50% of patients do not meet adherence requirements (A. 
Ammassari et al., 2001; David R. Bangsberg et al., 2003; Ickovics, et al., 2002).  Other studies 
have found that only 4-30% of HIV patients were able to achieve a 95% adherence rate (Golin et 
al., 2002; Paterson, et al., 2000). Nonadherence to prescribed antiretroviral medications may 
result in failure to achieve viral suppression, increased HIV replication, and can lead to the 
development and transmission of drug resistant strains of HIV. Consequently, health care 
providers are increasingly providing patients assistance with medication adherence to reduce the 
chances of treatment failure and decrease development of drug resistant strains being transmitted 
to the public (Smith, et al., 2004). 
Currently, no gold standard exists for assessing medication adherence among health care 
providers and the methods for assessment vary. Some providers may assess adherence every 
visit; whereas, others may assess adherence only with patients who are at-risk for nonadherence 






blood 48 weeks after treatment initiation), immunologic failure (i.e., CD4 cells decrease in 
number), or clinical progression of HIV. Further, health care providers often lack sufficient time, 
education and resources to adequately prepare patients beginning treatment regimens to increase 
rates of adherence (Gerbert, Bronstone, Clanon, Abercrombie, & Bangsberg, 2000). Due to the 
variety of frequency and methods of assessment and intervention, research should focus on 
establishing a standardized intervention that offers education regarding antiretroviral 
medications, enhances motivation to maintain adequate adherence, and provides problem-solving 
skills to enhance rates of adherence prior to initiation of treatment regimens. An electronic 
computer-based intervention would provide a standardized method of assessment and 
intervention which would greatly assist health care providers who currently have limited time 
constraints and resources to provide such an intervention. 
Interventions Designed to Improve Medication Adherence 
 Recent developments in intervention have found targeted intervention efforts using 
cognitive behavior therapy and motivational interviewing techniques to be effective at increasing 
adherence rates among patients with HIV (Parsons, Golub, Rosof, & Holder, 2007). The effects 
of these interventions have proven superior to the long-standing educational and self-monitoring 
approaches (Julius, Novitsky, & Dubin, 2009).  Although the development of effective 
interventions is a promising step, several practical barriers limit the likelihood of widespread 
dissemination and adoption of these methods. Intervention approaches that are delivered by 
clinical staff place additional time and expense burdens on health care systems and professionals 
that are already under heavy demands of patient care. To provide ideal interventions with fidelity 






The Present Study 
 An electronic, computer-based intervention could overcome several barriers and aid 
dissemination of an efficacious, cost-effective, and high-fidelity intervention in the clinic setting.  
Therefore, the present study was designed to develop an innovative computer-based electronic 
adaptation of an evidenced-based program to enhance medication adherence among individuals 
with HIV and evaluate the efficacy of the electronic intervention via a randomized controlled 
trial.  The development of a brief, computerized intervention targeting medication adherence 
may reduce the already demanding time constraints placed on physicians and health care 
providers.  Further, this intervention will be economically feasible and cost-effective and easily 
disseminated among patients who are at-risk for nonadherence, particularly patients who are 












A REVIEW OF THE LITERATURE 
 The introduction of Acquired Immune Deficiency Syndrome (AIDS) in 1981 initiated a 
global pandemic that has resulted in a plethora of worldwide problems including premature 
death, debilitating health concerns, financial hardship both on the micro and macro economy, 
and a deepening of socioeconomic and gender disparities (Pence et al., 2008; Sohler, Li, & 
Cunningham, 2009; Tsai, Chopra, Pronyk, & Martinson, 2009). Within the last three decades, 
over 25 million people worldwide have died as a result of the disease (Merson, 2006). The 
amount of people living with human immunodeficiency virus (HIV), which causes AIDS, has 
more than tripled since 1990, with an estimated 33.4 million people currently living with HIV 
worldwide (UNAIDS/WHO, 2009).  In the United States, it was estimated that more than 1.1 
million adults and adolescents were living with HIV infection in 2006 and approximately 56,000 
people are infected annually (Hall et al., 2008).  It is expected that if the HIV transmission rate in 
the United States remains constant, within the next decade, the number of new infections will 
increase to more than 75,000 annually.  This data has resulted in a renewed urgency to combat 
the HIV epidemic in the United States by reducing the number of new infections, increasing 
access to care, and reducing HIV-related health disparities (see National HIV/AIDS Strategy for 
the United States, 2010).  Epidemiological data also suggests that the spread of HIV peaked after 
the introduction of antiretroviral medication in 1996, yet it continues to remain at a disturbingly 
high level.   
 Pharmacological treatment advances have drastically reduced HIV-related morbidity and 
mortality.  The inception of highly active antiretroviral therapy (HAART) shifted HIV/AIDS 






treatment has been shown to suppress viral replication, preserve immune functioning, maintain 
or improve quality of life, and reduce HIV-related morbidity and mortality (Blalock & Campos, 
2003; Rathbun, Lockhart, & Stephens, 2006; H. Wang, et al., 2009). Once treatment is initiated, 
it is expected that treatment will be lifelong.  HAART regimens have been notoriously harsh and 
complex, requiring a combination of three or more drugs belonging to two classes of 
antiretroviral agents (Blalock & Campos, 2003; Rathbun, et al., 2006).  Medication regimens are 
individually tailored to the patient, therefore the number of pills and frequency of dosage the 
patient is required to take the medication varies.  Most regimens require multiple pills throughout 
the day in which some must be taken on an empty stomach, while others must be taken with 
meals or before or after doses of other medications.  
Fortunately, pharmacological advances have yielded newer drugs with longer half-lives 
generating once-daily regimens which simplify the dosing schedule and has the potential for 
increased adherence. Disadvantages inherent with the once-daily regimen include poorer 
tolerability with higher doses and potential for increased development of treatment resistance in 
patients who do not adequately adhere to the regimen (Rathbun, et al., 2006).  Patients may find 
it difficult to tolerate HIV medications due to a number of negative side effects and drug 
toxicities, some of which may be serious and potentially life-threatening such as Hepatotoxicity, 
hyperglycemia, high cholesterol, and Hyperlipidemia which can lead to heart disease and 
pancreatitis.  Other side effects may not be potentially life-threatening, however, these symptoms 
may be very difficult to tolerate and may include neurocognitive deficits, psychiatric side effects, 
abnormal fat distribution, decreased bone density, skin rash, nerve problems, increased bleeding, 






Although HAART is generally associated with improved quality of life, these negative 
side effects reduce quality of life, especially in patients who currently do not experience 
symptoms of HIV or AIDS (Paterson, et al., 2000).  Patients may decide that the costs of 
antiretroviral therapy outweigh the benefits of treatment and may choose to delay therapy or not 
adhere to the prescribed regimen.  Complex regimens and negative side effects pose multiple 
barriers to adherence and many challenges for people taking antiretroviral medications. 
Adherence to Prescribed HIV Treatment Regimens 
Adherence refers to the “extent to which a patient’s behavior coincides with medical or 
prescribed health advice” (Julius, et al., 2009, p. 34).  Behaviors of nonadherence may include 
premature termination of therapeutic regimen, inaccurate use of medications, taking drug 
holidays, using treatments or substances not prescribed, and failure to attend medical 
appointments (Cox, 2009).  Unlike many other chronic illnesses which require an adherence rate 
around 80% for adequate control, effective HIV treatment requires a stringent adherence rate of 
95% or better to optimize the chances of treatment success and reduce the likelihood of 
developing drug resistant strains of HIV.  Rates of adherence to HIV regimens is closely 
associated with viral suppression, development of drug resistant strains, clinical disease 
progression, and mortality (D. R. Bangsberg et al., 2000; D. R. Bangsberg et al., 2001; García de 
Olalla et al., 2002; Hogg et al., 2002; Paterson, et al., 2000).  Antiretroviral treatment adherence 
rates of 70%-80% have been associated with high rates of treatment regimen failure and 
emergence of resistant strains of the virus, suggesting that partial adherence may be more 






consistent adherence has been associated with health, economic, and psychosocial benefits 
worldwide.  
Numerous studies have demonstrated improved immunological responses and viral 
suppression among patients who adhere to antiretroviral medications.  Wang and colleagues 
(2009) examined the relationship of adherence to HAART medications and treatment outcomes 
measured via CD4 cell counts and occurrence of HIV/AIDS-related opportunistic infections.  
Among this sample, the most common reasons for missing doses or discontinuing treatment 
prematurely included: (1) forgetting medication; (2) being away from home; (3) being too busy; 
and (4) negative side effects from the regimen. Participants were dichotomized as either 
consistent adherers or nonadherers. The results demonstrated that participants who adhered to 
their prescribed regimen had greater CD4 cell growth, which is indicative of immunologic 
recovery, and were significantly more likely to be free from opportunistic infections compared to 
nonadherent participants.   
Additionally, adherence has been associated with suppression of viral loads below limits 
of detection, slowing progression of HIV and delaying the development of AIDS.  In a double-
blind, randomized controlled trial conducted across four countries, among individuals who 
maintained 90% or better adherence, no participants progressed to AIDS status during the study 
period; however, among participants who were less than 50% adherent, 8% progressed to AIDS 
during the study period.  Among participants with rates of adherence between 51-89%, 38% 
progressed to AIDS (Montaner et al., 1998). More recent studies have demonstrated similar 
results and have further shown that the stringent adherence cut-off of 95% is necessary for good 






virological and immunological responses to treatment and are at an increased risk of developing 
drug resistance to two or more drugs (Kitahata et al., 2004; Lima et al., 2008).  Individuals with 
low rates of adherence are over five times more likely to experience disease progression than 
moderate- and high-adherers (Kitahata, et al., 2004).  The progression from HIV status to AIDS 
greatly contributes to increased morbidity and mortality.  
Since its inception, HAART has greatly reduced the number of deaths due to HIV/AIDS. 
Multiple randomized controlled trials in patients who currently meet an AIDS diagnosis or have 
a history of an AIDS-defining illness (indicated by CD4 cell counts <200 cells/mm
3
) provide 
strong support that antiretroviral regimens improve survival and delay disease progression 
("Zidovudine, didanosine, and zalcitabine in the treatment of HIV infection: meta-analyses of the 
randomised evidence. HIV Trialists' Collaborative Group," 1999; Zolopa et al., 2009).  Early 
initiation of treatment may prevent damage to organs and neurocognitive decline associated with 
viral replication during early stages of treatment (Panel on Antiretroviral Guidelines for Adults 
and Adolescents, 2009).  However, the potential benefit of reduced mortality is contingent on 
long-term adherence to antiretroviral medications. Individuals who adhere at the beginning of 
HIV treatment initiation have a longer life expectancy than those who do not adhere or receive 
no treatment (Aracena-Genao, Navarro, Lamadrid-Figueroa, Forsythe, & Trejo-Valdivia, 2008).  
Further, patients who are non-adherent are almost 4 times more likely to die than an adherent 
patient on the same therapeutic regimen (García de Olalla, et al., 2002).  HIV positive 
individuals with better immunological responses, fewer opportunistic infections, and longer life 
expectancy require fewer medical resources throughout their life span and place less of a burden 






Antiretroviral medications are expensive and some patients choose to skip dosings in 
order to assuage the economic burden.  Unfortunately, this strategy may inevitably result in 
additional unanticipated hospital expenses.  Adherence to HAART has been associated with 
lower hospital expenses, shorter hospital stays, and decreased hospital readmissions (H. Wang, et 
al., 2009).  Cost-effectiveness analyses have indicated that the cost of antiretroviral medications 
may be offset by decreased hospitalization costs and slower disease progression which also 
enables the patient to continue working and living a productive life (Nosyk, Sun, Li, Palepu, & 
Anis, 2006).  Wang and colleagues (2009) found an association between consistent high levels of 
adherence and reduced utilization of medical resources (e.g., decreased number of nontrauma 
hospitalizations, reduced hospital expenses).  Increased risk of compromised health due to 
immunodeficiency caused by HIV likely diminishes quality of life among patients. 
Consistent adherence to HIV regimens has been found to be the most important factor in 
improving quality of life among patients (H. Wang, et al., 2009).  Patients who are adherent have 
demonstrated better physical health outcomes and physical functioning, greater vitality, better 
social functioning and mental health compared to patients who do not adhere (H. Wang, et al., 
2009).  However, the relationship between adherence and quality of life is reciprocal and quite 
complex.  Patients who are asymptomatic may see a reduction in their quality of life with early 
initiation of HAART (Low-Beer et al., 2000; Nieuwkerk et al., 2001; Zinkernagel et al., 1999).  
Negative side effects and drug toxicities associated with drug regimens can be difficult to 
tolerate and may result in insufficient rates of adherence or premature termination of treatment.  
Additionally, patients must adhere to strict regimen protocols that may require rigid time 






However, with the improvement of antiretroviral medications, side effects have become more 
tolerable and regimens more simplistic.   
More recent studies have found long-term improvements in quality of life among both 
symptomatic and asymptomatic patients (S. B. Mannheimer et al., 2005).  Mannheimer and 
colleagues (2005) conducted a longitudinal study which demonstrated improvements in quality 
of life over time in HIV patients prescribed antiretroviral therapy.  The results indicated 
significant improvements in physical components as early as one month after initiation of 
HAART and improvements in mental functioning after four months with improvements being 
sustained over the course of one year.  Participants reporting 100% adherence had the greatest 
gains in both physical and mental functioning at all four follow-up points (month 1, 4, 8, and 12); 
whereas, participants reporting 80-99% adherence had smaller gains and participants reporting 
less than 80% adherence displayed lower levels of quality of life at follow-up compared to their 
baseline scores.  This demonstrates the importance of maintaining near perfect levels of 
adherence and the benefits HIV treatment can have on quality of life.  Nonadherence to 
antiretroviral regimens is an important predictor for losing the long-term clinical and economic 
benefits of treatment.   
The Problem of Nonadherence to HIV Treatment 
The proportion of individuals with HIV who maintain an optimal level of adherence is 
relatively small. Multiple studies have found that as many as 50% of patients do not meet 
adherence requirements (Adriana Ammassari et al., 2002; Gardner, Burman, Maravi, & 
Davidson, 2006; Ickovics, et al., 2002). Other studies have found that only 4-31% of HIV 






Further, rates of non-adherence tend to decline over time and with subsequent regimens 
(Gardner, et al., 2006; Ickovics, et al., 2002; Johnson, et al., 2003; Paterson, et al., 2000).   
Gardner and colleagues (2006) examined the durability of patient adherence to HAART 
regimens by evaluating changes in adherence throughout the course of an initial treatment 
regimen and then examining adherence over successive regimens.  Results demonstrated that 
adherence was closely associated with initial regimen duration; however, adherence tended to 
decrease throughout the course of the initial regimen and trended downward with subsequent 
regimens.  These results provide support that adherence to antiretroviral medications tends to 
decrease over time, even among patients who are very adherent.  Additional studies have 
indicated that poor adherence early in treatment is among the most common reason for 
discontinuing HAART treatment and experiencing treatment failure (d'Arminio Monforte et al., 
2000; Mocroft et al., 2001; Moss et al., 2004). This downward trend in adherence has been 
termed “adherence fatigue” and demonstrates the need for effective interventions in 
strengthening medication adherence not only for patients initiating antiretroviral therapy, but 
throughout the course of treatment as well.  
 As HIV medications have become more simplistic and advanced, leading to a decrease in 
toxicity and negative side effects, discontinuation of therapeutic regimens due to intolerance and 
toxicity has declined over time; however, intolerance and toxicity remain the major cause of HIV                         
regimen discontinuation (Cicconi et al., 2010).  Cicconi and colleagues (2010) investigated 
reasons for first-line treatment discontinuation among patients initiating HAART regimens 
during the early stages of HAART beginning in 1997 to more recent HAART regimens ending in 






causes of treatment discontinuation during the first 12 months of treatment.  Interestingly, 
modification of initial medication regimens due to poor adherence did not change across time 
even though more recent regimens have a lower pill burden. The authors suggested this was 
likely a result of little change in the attitude towards antiretroviral therapy across time.  Further, 
patients with a history of injection drug abuse and patients younger than age 30 had a tendency 
towards higher rates of discontinuation due to poor adherence. These results reflect the impact 
stigma and negative attitude towards HIV medications have on adherence and expand on the 
existing literature which has revealed specific factors associated with heightened risk for poor 
adherence. 
Barriers to Adherence 
 Numerous biological, behavioral, and social factors influence medication adherence. 
Biological factors include disease status, host immunology, genetics, and characteristics of the 
medications, including drug potency and pharmacology (Friedland, 2006).  Patients who are 
asymptomatic have a higher rate of nonadherence than patients where the disease is more 
advanced and may have progressed to AIDS status.  Individuals who experience symptoms of 
HIV/AIDS perceive nonadherence to HIV regimens as a higher risk for complications from HIV 
(Gao, Nau, Rosenbluth, Scott, & Woodward, 2000).  The most reported deterrents of adherence 
among patients is adverse side effects of the regimen, the number of pills, and dosing restrictions 
(i.e., frequency and if they require food or water).  Extensive toxicity and side effects associated 
with HAART may greatly influence a patient’s willingness to adhere to the regimen.  Both 
transient (diarrhea, nausea) and long-lasting (Lipodystrophy, neuropathy) side effects account for 






al., 2000; Mocroft, et al., 2001).  Further, pharmacological characteristics of the prescribed 
medication play an important role in adherence.  The more recently developed once-daily 
regimens are better tolerated, more flexible, and more forgiving if patients miss a dose.  Several 
of these medications have long elimination half-lives (between 24-50 hours) which mitigate the 
increased risk of viral rebound and development of drug resistance when a patient misses a dose 
(Conway, 2007).  Medication regimens that are simplistic and best conform to the patient’s 
lifestyle and schedule may predict better adherence.    
Behavioral factors, which often lie at the root of treatment failure, include accurate 
knowledge regarding the regimen, cognitive functioning (i.e., remembering the regimen and 
having the capacity to understand dosing requirements), psychological functioning (i.e., 
depression, stress, feeling hopeless), motivation, and skills (Adherence to Long-Term Therapies: 
Evidence for Action, 2003; Friedland, 2006). Forgetting to take medication is the most frequently 
cited reason for nonadherence (M. A. Chesney et al., 2000).  Many patients report failing to 
remember to take the medications when they are not at home, being uncertain about how to take 
the medications, and believing that they cannot adhere to the strict regimen requirements 
(Kathleen Johnston Roberts, 2000).  Further, difficulty understanding the medication regimen 
hinders adherence as well.  Approximately 25% of patients admit to not understanding how to 
follow their regimens and report confusion over pill number and sequencing (Catz, Kelly, 
Bogart, Benotsch, & McAuliffe, 2000; M. A. Chesney, et al., 2000).  Adequate cognitive 
functioning and psychosocial issues often contribute to the ability to understand the regimen 






Lower levels of adherence to HIV regimens have been associated with cognitive deficits 
in executive functioning tasks which require attention, mental flexibility, and reasoning skills 
(Albert et al., 1999; Charles H. Hinkin et al., 2004).  Additional impairments associated with 
adherence include memory, attention, and psychomotor speed (Albert, et al., 1999; C. H. Hinkin 
et al., 2002; Waldrop-Valverde et al., 2006).  One of the stronger predictors of nonadherence is 
impaired cognitive functioning due to active alcohol and substance use.  Recreational drug and 
alcohol use have consistently been associated with poor levels of adherence (Halkitis, Shrem, 
Zade, & Wilton, 2005; Mugavero et al., 2006; Murphy, Roberts, Martin, Marelich, & Hoffman, 
2000; Rothlind et al., 2005; Waldrop-Valverde, et al., 2006; Witteveen & van Ameijden, 2002).  
Ingesting substances that result in temporary cognitive impairments can cause missed doses and 
combining certain illicit drugs with antiretroviral medications can produce unwanted negative 
side effects and may also strain the liver or lead to possible overdose (Halkitis, et al., 2005).  In 
order to avoid these negative consequences, individuals may take their antiretroviral medications 
during the week and discontinue their use on weekends to drink alcohol or use other substances.  
These lapses in adherence, often referred to as “drug holidays”, may contribute to the 
development of viral resistance and more rapid disease progression.  Individuals with HIV who 
also abuse substances are at a heightened risk for nonadherence due to acute and potentially 
chronic cognitive impairment, mental health functioning, and educational challenges frequently 
experienced among this population. 
As demonstrated among the substance abusing population, the HIV pandemic has 
widened the gap of socioeconomic disparities.  AIDS has disproportionately affected the lower 






individuals living in poverty.  Among this population, poor education and low rates of reading 
literacy have posed many challenges to HIV medication adherence.   Kalichman and colleagues 
(1999, 2000) were among the first to investigate the ability of patients with HIV to comprehend 
medical information and the association between literacy skills and adherence to medication 
regimens.  The authors found that HIV patients with limited literacy had less general knowledge 
of HIV and their treatment regimen compared to patients with adequate literacy skills.  Further, 
these patients reported significantly worse biological outcomes as evidenced by lower CD4 cell 
counts and being less likely to have an undetectable viral load (S. C. Kalichman et al., 2000; S. 
C. Kalichman, Ramachandran, & Catz, 1999).  Patient literacy level has been associated with 
more than a three-fold greater likelihood of missing doses (Wolf et al., 2007).  Additionally, 
evidence suggests that self-efficacy may mediate the effect of literacy on adherence (Wolf, et al., 
2007).  It appears that the patient’s belief about whether he or she can successfully execute the 
prescribed medication regimen may play a stronger role in improving medication adherence than 
only providing knowledge of HIV and the treatment. 
In addition to cognitive functioning and substance abuse, other psychosocial issues have 
been associated with nonadherence, including depression, stress, hopelessness, anxiety, and 
social support.  Depression and stress are among the most significant predictors of adherence (M. 
Chesney, 2004).  Among people living with HIV, approximately 37% meet criteria for a 
depressive mood disorder (Asch et al., 2003; Bing et al., 2001).  Depression has been associated 
with regression of HIV-related biological outcomes, progression to AIDS status, higher levels of 
substance use, and mortality (Ironson et al., 2005; Jane Leserman, 2008; Jane Leserman, Ironson, 






Cherner, 1996).  Further, stressful life events have been associated with poorer adherence 
(Adriana Ammassari, et al., 2002; Catz, et al., 2000).  People living with HIV may experience 
high levels of stress, which lead to a cyclical pattern of decreased adherence to medication, 
which results in additional stress.  Having a strong social support system may buffer against 
some of the negative effects of increased stress associated with HIV and provide the patient 
emotional support to increase motivation to adhere to their medication regimen.  Lack of social 
support has been identified as an important risk factor for nonadherence (Adriana Ammassari, et 
al., 2002).   
Social factors such as availability of resources, access to care and treatment, race, gender, 
and stigma play an important role in adherence as well (Friedland, 2006). Implementing the 
medication regimen into daily life and being unable to take medications privately while at work 
or in public pose a significant barrier to patients. Concerns about confidentiality and 
stigmatization may hinder adherence and therapeutic success.  Women, in particular, are often 
very secretive about their HIV status and reluctant to take their medications that may disclose 
their HIV status due to fear of rejection and stigmatization (Carr & Gramling, 2004).  It is 
imperative that health care providers address these issues with patients, particularly those 
beginning a new regimen or who are nonadherent.  
Consequences of Nonadherence 
 Antiretroviral medications have proven to be highly effective in reducing viral 
replication, improving clinical outcome, and decreasing mortality (M. Chesney, 2004).  Failure 
to adequately adhere to medication regimens places patients at a heightened risk of treatment 






maintain expected immunologic and clinical benefits from treatment is failure to adequately 
adhere to antiretroviral regimens (Conway, 2007).  There are three types of treatment failure in 
HIV: (1) virologic failure; (2) immunological failure; and (3) clinical progression.  Virologic 
failure occurs when antiretroviral medications fail to reduce the amount of HIV in the blood.  
Viral load indicates the amount of HIV in a sample of blood and is the most important indicator 
of how well a medication regimen is working.  If a patient’s viral load fails to decrease or 
repeatedly rises after having decreased, virologic failure has occurred.   
        Inadequate adherence may also result in immunologic failure as indicated by decreased 
CD4 cell count.  CD4 cells play a vital role in the immune response by signaling other cells to 
execute their functions.  A healthy person has a CD4 count of 800-1200 per cubic millimeter 
(mm
3
) of blood (Klimas, et al., 2008).  As HIV progresses, it destroys CD4 cells and develops 
holes in the immune repertoire, decreasing immunologic functioning.  When CD4 cell counts fall 
below 200 cells/mm
3
 vulnerability to serious opportunistic infections and cancers increase, 
signaling that the immune system is not responding to antiretroviral medications and clinical 
progression is imminent.  Clinical progression occurs with the presence or recurrence of HIV-
related events despite at least 3 months of antiretroviral therapy (Panel on Antiretroviral 
Guidelines for Adults and Adolescents, 2009).  Virologic failure, immunologic failure, and 
clinical progression may occur independently or concurrently; however, virological failure often 
occurs first, followed by immunological failure, then clinical progression.  Treatment failure may 
happen over the course of months to years (d'Arminio Monforte, et al., 2000).   
In addition to treatment failure, inadequate adherence may result in the development of 






of suboptimal drug concentrations.  HIV can rapidly mutate to develop resistant strands of the 
virus and can result in resistance for an entire class of antiretroviral medications, which, 
consequently, causes HAART to be ineffective and limits future treatment options (Conway, 
2007; Seth C. Kalichman & Malow, 2004).   
The transmission of treatment resistant strains of HIV is a serious public health concern 
in the prevention and control of HIV.  Since the inception of HAART, prevalence rates of 
transmitted drug resistance range from 10-20% in developed countries (Grant et al., 2002; Ibe et 
al., 2003; Russell et al., 2009; Shet et al., 2006).  Individuals with HIV who contract a drug-
resistant strand of the virus have the potential to develop superinfection which is caused by 
infection with multiple strains of HIV and may include strains that are treatment-resistant.  For 
example, an individual who has developed resistance to one class of antiretroviral medications 
can be reinfected with an HIV variant that is resistant to a different class of HAART medications 
(Seth C. Kalichman & Malow, 2004).   This variation can be transmitted to uninfected persons in 
addition to those already infected with HIV.  Drug resistance is a concern for not only patients 
currently on HIV treatment, but for those who are newly infected with the virus and for those 
who are naïve to treatment or initiating drug therapy (Klimas, et al., 2008).   
 In addition to biological consequences, nonadherence has also played a role in economic 
costs at both the macro- and micro-level of society.  In the United States, the overall cost for HIV 
care generally exceeds $20,000 per person annually (Freedberg et al., 2006).  Among patients 
whose CD4 cell counts are <50 cells/mm
3
, the cost of care is more than double that of patients 
with CD4 counts >350 cells/mm
3 
(Panel on Antiretroviral Guidelines for Adults and 






more advanced disease status are from non-antiretroviral medications and increased 
hospitalizations.  Patients who adhere to their HAART regimens have significantly lower 
hospital readmissions and decreased stays contributing to reduced utilization of hospital 
resources (Moore, 1998; Nosyk, et al., 2006).  Additionally, second-line treatment for HIV 
among individuals who develop resistance to a particular class of antiretroviral medications is 
more expensive than first-line treatments further demonstrating the cost-effectiveness of 
adherence to HIV regimens (Adherence to Long-Term Therapies: Evidence for Action, 2003).  In 
addition to direct medical costs, individuals with HIV have higher rates of clinical progression, 
morbidity, and mortality.  Patients who progress to AIDS status or experience HIV symptoms 
may become unable to work or perform necessary daily tasks.  This loss of labor time as a result 
of morbidity and mortality and time spent by others caring for the patient demonstrates the 
indirect economic costs of nonadherence among individuals with HIV and their families 
(Marlink et al., 2008).    
 On the macro-level, HIV/AIDS impacts people during their most productive years of life.  
A majority of the individuals who suffer from HIV/AIDS are between the ages of 15-45.  
Complications from HIV and clinical progression decrease the individual’s ability to contribute 
to society and contribute to reduced productivity within a society.  Labor sector shortages and 
intergenerational impacts from lowered health and educational investment in children have been 
well documented in developing countries (Jackson, 1994; Marlink, et al., 2008; Tekola, Reniers, 
Haile Mariam, Araya, & Davey, 2008; Zaba, Whiteside, & Boerma, 2004).  Increasing levels of 
adherence among HIV patients reduces rapid progression of the disease and further increases 






the burden on the health care system.  The development of interventions, even those that are very 
expensive and moderately effective, which target increasing adherence has been demonstrated to 
be cost-effective (Freedberg, et al., 2006; Goldie et al., 2003). 
Models of Medication Adherence 
Information-Motivation-Behavior Skills Model 
 Current research concerning interventions addressing HIV medication adherence is 
dominated by models that address social and cognitive aspects of behavior, such as attitudes, 
self-efficacy, and values concerning adherence, and social support. The most predominant model 
is the Information-Motivation-Behavioral (IMB) Model which ascertains that behaviors result 
from knowledge of accurate information, personal and social motivation, and behavioral skills (J. 
D. Fisher & Fisher, 1992). This model has been empirically supported and multiple efficacious 
interventions based on this model have been applied to a broad range of health behaviors such as 
HIV sexual risk behavior, breast self-examination, and motorcycle safety gear utilization 
(Amico, Toro-Alfonso, & Fisher, 2005; Ferrer, 2010; J. D. Fisher, Fisher, Misovich, Kimble, & 
Malloy, 1996; W. A. Fisher, Fisher, & Harman, 2003; Starace, Massa, Amico, & Fisher, 2006).     
 Prior to the inception of antiretroviral therapy, Fisher & Fisher (1992) established three 
fundamental determinants to reduce HIV/AIDS risk behavior to prevent transmission: (a) 
accurate information pertaining to transmission of HIV and methods of prevention; (b) 
motivation to change HIV risk behaviors; and (c) possessing the behavioral skills necessary to 
change risky behaviors.  After the introduction of HAART, Fisher and colleagues applied this 
conceptualization to develop the IMB model of antiretroviral (ART) adherence (J. D. Fisher, 






 On a broad level, this model posits that possession of information, motivation, and 
behavioral skills related to HIV medication adherence are primary determinants of adherence to 
antiretroviral medication regimens and will be indicative of HIV-related health outcomes.  In 
order for patients to meet the strict HIV adherence requirements, the individual must have 
accurate information regarding his or her regimen.  This includes information regarding the 
individually-tailored medication regimen and factors that constitute correct utilization and 
adequate adherence, any side effects associated with the regimen, and potential drug interactions 
or toxicities.  This component also addresses faulty heuristics and implicit theories regarding 
HIV medications and adherence (Starace, et al., 2006).  For example, a patient may believe that 
if he or she is feeling well and not experiencing HIV-related symptoms, then he or she is taking 
enough medications even though the adherence level is well below that recommended.  These 
often inaccurate heuristics may play a strong role in decision-making related to adherence 
behaviors and influence motivation to follow the medication guidelines.   
      A patient’s motivation to adhere to the prescribed medication regimen plays a critical 
role in adherence-related behaviors.  Fisher et al. (2006) describe two categories of motivation: 
personal motivation and social motivation.  Personal motivation consists of the individual’s 
attitudes and beliefs regarding the potential benefits and costs associated with varying levels of 
adherence.  In order for patient’s to establish and maintain optimal adherence long-term, he or 
she must possess favorable beliefs regarding antiretroviral medications and the health-related 
outcomes.  Social motivation is determined by the individual’s perceived level of support from 






the wishes of significant others.  The possession of accurate information and motivation are 
prerequisites for patients to enact the behavioral skills required for optimal adherence. 
 Since antiretroviral therapy is complex and a life-long treatment, patients must have the 
ability to perform certain behavioral skills in order to meet adherence requirements for greatest 
benefit from the regimen.  These behavior skills encompass a range of objective and perceived 
abilities which include: (a) acquiring, self-cueing, and self-administering medications; (b) 
incorporating the regimen into daily life; (c) identify and minimize or cope with the negative side 
effects; (d) stay current with HAART and adherence-related facts; (e) acquire social support for 
adherence; (f) communicate effectively with health care providers; and (g) reinforcement for 
maintaining adherence over time and overcoming barriers to adherence.  Each of these skills play 
a vital role in maintaining optimal levels of adherence.  
 Within this model, both information and motivation are indirectly associated with 
adherence-related behavior by means of influencing acquisition and utilization of behavioral 
skills which are directly related to adherence behaviors.  These three components encompass a 
wide range of factors associated with nonadherence to prescribed HIV medication regimens and 
identify both idiosyncratic and ecological factors that may moderate adherence.  This is the first 
model of HIV medication adherence to provide a comprehensive, multivariate, theoretical 
approach (Amico, et al., 2005).   
Transtheoretical Model of Behavior Change 
 The transtheoretical model (TTM) coincides with the IMB model by assessing the 
individual’s readiness to change health-related behaviors.  This process consists of five 






including smoking cessation, alcohol, safer sex practices, and adherence to medical 
recommendations among patients with diabetes, arthritis, and obesity (Grimley, Riley, Bellis, & 
Prochaska, 1993; Keefe et al., 2000; Miller & Rollnick, 1991; J. O. Prochaska et al., 1994; 
Sarkin, Johnson, Prochaska, & Prochaska, 2001; Vallis et al., 2003).  This model asserts that 
people progress through a series of stages that occur over time and utilizes a series of core 
constructs which include decisional balance and self-efficacy.  In order for behavior change to 
occur, individuals will progress through the series of stages and accomplish a variety of specific 
tasks at each stage; however, it is not uncommon for relapse back into a previous stage to occur.  
Before achieving long-term maintenance of the desired behavior an individual may cycle and 
recycle through the stages multiple times. 
 The stages of change consist of five specified changes: precontemplation, contemplation, 
preparation, action, and maintenance (DiClemente & Prochaska, 1998; James O. Prochaska & 
DiClemente, 1983; J. O. Prochaska, et al., 1994).  In the initial stage of precontemplation, the 
individual is not currently considering changing a behavior.  Most individuals in this stage do not 
foresee their behavior as a problem and do not see a need for change.  Oftentimes, however, the 
individual’s social support network sees the problematic behavior and, when confronted, the 
individual may become very defensive.  An individual in this stage may recognize occasionally 
missing doses of the antiretroviral medication, but see no reason to change their behavior in the 
foreseeable future.  This person fails to recognize the consequences of inadequate adherence and 
may not have accurate information regarding the importance of adhering to the prescribed 
regimen or know what constitutes adequate adherence for HIV medications.  Patients with HIV 






 The next stage is contemplation in which a person is aware that he has a problem and is 
currently considering making a change, but has not yet committed to action.  A patient with HIV 
in this stage will recognize that taking “drug holidays” on the weekends to avoid the negative 
effects of mixing substances with the antiretroviral medications is problematic and is aware of 
the potential health risks associated with this behavior; however, he has not committed to an 
action plan to stop this risky behavior.  The preparation stage is characterized by intention of 
taking action to change the behavior within the next month and may be marked with small steps 
toward attempting to change the behavior.  In this stage, a patient may increase the number of 
medications taken weekly, yet still not maintain a 90-95% adherence rate that is adequate for 
desired clinical outcomes. 
 In the action stage, the person modifies personal and environmental factors that 
contribute to the problematic behavior.  This stage is often very challenging and takes a 
considerable amount of time and commitment to overcoming the obstacles (James O. Prochaska 
& Norcross, 2001).  This stage lasts from one day to six months if the person successfully 
modifies the negative behavior.  If a person is able to sustain a 95% adherence rate for more than 
six months then he has successfully moved into the final stage of the model which is the 
maintenance stage.  In this stage, the individual maintains the desired behavior and steps are 
taken toward avoiding relapse of the unwanted behavior.  By this stage, the individual has gained 
confidence that he will be able to maintain the changes made (James O. Prochaska, 2008). 
 In addition to the stages of change, several core constructs are essential to understanding 
movement from one stage to the next.  The first construct is decisional balance which identifies 






DiClemente, 1983).  In essence, decisional balance is weighing the costs and benefits of 
changing the behavior versus the costs and benefits of maintaining status quo.  As individuals 
progress through the stages of change a shift of the costs and benefits is observed.  For instance, 
in the precontemplation stage, the costs of changing the behavior clearly outweigh the benefits; 
whereas in the preparation stage onward the opposite pattern emerges (J. O. Prochaska, et al., 
1994; Sun, Prochaska, Velicer, & Laforge, 2007).  Individuals who are in the contemplation 
stage and experience ambivalence do so as a result of perceiving the costs and benefits of 
changing the behavior being essentially equal (James O. Prochaska, 2008).  This demonstrates 
the importance of increasing the individual’s awareness of the benefits of changing the 
problematic behavior and decreasing the costs in order to progress to the action stage. 
 The second construct, self-efficacy, is an important component to motivate an individual 
for behavior change and can reasonably predict treatment outcome (Miller & Rollnick, 1991).  
Self-efficacy is the belief an individual has in his or her capability to successfully perform a 
particular behavior, such as taking antiretroviral medications as prescribed.  An individual’s self-
efficacy is shaped by information from past experiences (e.g., accomplishments and failures), the 
perception of others’ accomplishments, feedback regarding one’s ability to perform the desired 
behavior, and one’s physiological state (Bandura, 1977).  Early studies investigating the stages of 
change demonstrated that self-efficacy was the only variable related to long-term successful 
behavior change among addictive behaviors, particularly smoking cessation (James O. Prochaska 
& DiClemente, 1982).  Among the HIV population, inconsistent data exists regarding the role 
self-efficacy plays among medication adherence.  Mounting evidence suggests a mediating role 






Caruthers, 2008; Cook, McCabe, Emiliozzi, & Pointer, 2009; Godin, Côté, Naccache, Lambert, 
& Trottier, 2005; Malcolm, Ng, Rosen, & Stone, 2003).  Godin and colleagues (2005) found that 
high self-efficacy in combination with a positive attitude towards antiretroviral medications 
predicted better adherence compared to participants with low perceived self-efficacy and a 
negative attitude.    Developing positive expectations regarding one’s ability to perform the 
prescribed HIV regimen daily and in challenging circumstances, as well as instilling positive 
expectations regarding outcomes of taking the medication are an important part in improving 
adherence.   
 Utilization of the core constructs of the transtheoretical model (i.e., stages of change, 
decisional balance, self-efficacy) has become increasingly popular among health care providers 
to motivate HIV patients to maintain adequate adherence levels (Cook, et al., 2009; Holstad, 
DiIorio, & Magowe, 2006; Safren, Otto, & Worth, 1999).  The application of the transtheoretical 
model within the framework of the information-motivation-behavioral skills model has led to the 
development of efficacious interventions for improving adherence among this population.   
Interventions Designed to Enhance Medication Adherence 
 Significant progress has been made in developing efficacious interventions for enhancing 
adherence, but several barriers limit wide dissemination and adoption of these practices. Health 
care providers have implemented a variety of interventions designed to increase adherence to 
medication regimens. Many of these interventions are multi-component and consist of using 
memory-prompting devices (i.e., medication cards, pillboxes), increasing social support, and use 
of motivational strategies. In a review of 88 descriptive and intervention studies, Sandelowski, 






to address problems with medication adherence. These interventions were directed towards 
knowledge, beliefs about HIV infection and antiretroviral therapy, social support, and behavioral 
strategies. Multiple studies have demonstrated that medication adherence is not a static, one-
dimensional behavior; rather, multiple emotional, cognitive, and behavioral factors that 
frequently change influence adherence (Johnson, et al., 2003; Remien et al., 2003; Sandelowski, 
Voils, Chang, & Lee, 2009).  Thus, effective interventions should target each of these factors and 
include components of education, skills-building, and problem-solving techniques (Johnson, et 
al., 2003). 
Memory Prompting Devices 
 Patients with HIV have frequently cited that “forgetting” to take their HIV medications is 
the most common reason for nonadherence (X. Wang & Wu, 2007).  The use of memory 
prompting devices may help to overcome this impediment.  Limited data exists examining the 
use of memory prompting devices only to enhance adherence.  Several studies used these devices 
in conjunction with a multi-component intervention.  One study investigated the use of a 
memory prompting device among HIV patients with cognitive impairments and found that 
adherence did improve among patients who used the electronic-reminder devices compared to a 
control group (Andrade et al., 2005). 
Mannheimer and colleagues (2006) conducted a randomized controlled trial investigating 
the efficacy of two different approaches to adherence interventions.  The first intervention was 
based on the IMB model and consisted of a trained staff member providing individually tailored 
support over time utilizing a standardized protocol which identified and addressed the 






second intervention utilized an electronic medication reminder system that was individually 
programmed to sound and flash at the time of all doses.  Participants in the first intervention 
demonstrated significant reductions in virologic failure, sustained CD4 cell counts, and better 
long-term adherence.  In contrast, participants in the electronic medication reminder condition 
showed higher rates of virological failure.  These results indicated that an interpersonal, 
multifaceted, long-term adherence intervention is efficacious in improving HIV adherence and 
suggests that this type of intervention is preferred over the medication monitoring devices. 
 Memory prompting devices have demonstrated improvements in adherence among 
patients with cognitive impairment; however, the use of these devices does not appear to have 
the desired effects among most patients taking antiretroviral medication (Andrade, et al., 2005; 
Sharon B. Mannheimer et al., 2006).  Several limitations are inherent within the utility of these 
devices including concerns about confidentiality and problems with the batteries and the device 
malfunctioning (Sharon B. Mannheimer, et al., 2006).  Additionally, the devices fail to address 
potential barriers associated with inadequate adherence such as medication side effects, 
substance use, depression, and psychosocial issues.  This demonstrates the need for 
comprehensive, multifaceted interventions for HIV adherence.  
Brief Motivation Interviewing (BMI) 
 Brief motivational interviewing (BMI) has demonstrated efficacy in promoting adherence 
to antiretroviral medications (Adamian, Golin, Shain, & DeVellis, 2004; DiIorio et al., 2008; 
Golin et al., 2006).  The foundation of BMI is within the transtheoretical model that describes 
stages of readiness to change and processes used by individuals to make intentional behavior 






ambivalence (Miller & Rollnick, 1991).  Initiation of behavior change is accomplished by 
creating dissonance between a patient’s current behavior and the target behavior, without 
judging, criticizing or blaming the patient or generating a hostile environment (Possidente, 
Bucci, & McClain, 2005).  This counseling style was originally developed for treatment with 
substance abuse and later adapted to facilitate change among a broader spectrum of health 
behaviors, including medication adherence. DiIorio and colleagues (2008) are among the first to 
conduct a randomized controlled trial investigating the use of motivational interviewing to 
promote adherence to antiretroviral treatments. This intervention aimed to build confidence, 
reduce ambivalence, and increase motivation for adherence through five counseling sessions 
over a three-month period. Results indicated that participants who received MI were taking a 
greater percentage of the prescribed doses and a significantly greater percentage of doses on time 
in comparison to a control group.  This study provides support for a client-centered approach that 
aims to increase intrinsic motivation and reduce ambivalence toward HIV medication adherence. 
 Not all studies investigating motivational interviewing, however, have demonstrated MI 
to be more efficacious than adherence education only.  One randomized controlled trial 
investigating the efficacy of MI on medication adherence among HIV patients with a history of 
alcohol problems and found that MI was not associated with changes in medication adherence, 
biological markers of disease progression, or alcohol consumption (Samet et al., 2005).  This 
study used self-reported measures in contrast to objective measures employed by DiIorio et al. 
(2008).  Further, the authors noted that sample size and limited exposure to the intervention for 






 Motivational interviewing addresses a very important component of behavior change; 
however, MI alone may not fully address the broad spectrum of factors associated with HIV 
medication adherence.  Multicomponent interventions based on the information-motivation-
behavioral skills model that incorporate MI into additional psychological techniques (i.e., 
cognitive behavioral therapy) have become more prevalent in the literature and demonstrated 
efficacy (Parsons, et al., 2007; Parsons, Rosof, Punzalan, & Di Maria, 2005; Sandelowski, et al., 
2009) 
Cognitive Behavioral Therapy 
Cognitive behavioral therapy (CBT) has been empirically supported to enhance 
adherence to antiretroviral medication (Holzemer et al., 2006; Koenig et al., 2008; Reynolds et 
al., 2008; Safren et al., 2009).  This intervention is one of the most widely used and empirically 
supported interventions to improve mental health functioning (Crepaz et al., 2008). The focus of 
CBT is on the interaction between maladaptive thought patterns, feelings, and behaviors. Crepaz 
et al. (2008) conducted a meta-analysis of cognitive behavioral interventions used to improve 
mental health functioning among individuals who are HIV-positive. The authors found that CBT 
was efficacious for improving psychological symptoms of depression, anxiety, anger, and stress 
compared to control groups.  Further, Safren et al. (2009) conducted a randomized controlled 
trial using CBT to treat HIV patients with depression and inadequate rates of adherence to 
antiretroviral medications. This study demonstrated significantly improved outcomes in both 
medication adherence and depression among patients receiving cognitive behavior therapy. 
Cognitive-behavioral interventions are among the most prevalent interventions used to 






randomized controlled trials have demonstrated significant changes in adherence post-
intervention utilizing these interventions (Goujard et al., 2003; Koenig, et al., 2008; Milam et al., 
2005; Parsons, et al., 2005; Safren, et al., 1999; Tuldrà et al., 2000).  These interventions focus 
on delivering accurate information to clients regarding HIV and the importance of adherence.  
Further, patients are engaged in a series of skills-building techniques and problem solving 
strategies.  This includes conducting a functional analysis of individual antecedents for 
medication adherence behaviors and teaching patients strategies to cope with side effects and 
increasing social support.  CBT provides patients with necessary skills to effectively cope with 
irrational thoughts and problem behaviors that contribute to medication nonadherence.  This 
intervention, in combination with motivational interviewing, addresses each component of the 
information-motivation-behavioral skills model and provides patients with a variety of strategies 
to improve adherence and clinical outcomes. 
Life Steps 
 The Life Steps program is a brief adherence intervention that combines components from 
several efficacious intervention approaches including both BMI and CBT, and has evidence of 
efficacy. Safren and colleagues developed the Life Steps program based on principles of 
cognitive behavior therapy, motivational interviewing, and problem-solving therapy to help 
patients identify and solve problems with medication adherence (Safren et al., 2001). This brief, 
single-session intervention is designed to provide patients with education and training to adhere 
to their medication regimen. The Life-Steps program consists of the following eleven 
informational, problem-solving, and cognitive behavioral steps: (1) introduction and 






communicating with providers; (5) coping with side effects; (6) formulating a daily medication 
schedule; (7) storing medication; (8) cues for pill taking; (9) guided imagery review of successful 
adherence in response to daily cues; (10) responses to slips in adherence; and (11) review of 
procedures. This intervention was based on previous evidence that brief, cognitive behavioral 
and problem-focused interventions improved medication adherence for a wide range of chronic 
illnesses such as diabetes and asthma (Bailey et al., 1990; Méndez & Beléndez, 1997).  More 
recent studies have supported the use of combined MI and CBT to improve medication 
adherence among HIV patients with a variety of comorbid conditions including alcohol abuse 
and depression (Parsons, et al., 2007; Safren, et al., 2009).  
 The development of the Life Steps program was based on empirically supported 
treatments for medication adherence. This program sought to combine techniques from MI, 
CBT, and problem-solving therapy into a brief, single session program. Safren and colleagues 
(2001) compared the Life Steps program to self-monitoring of medication adherence which has 
also been supported in the empirical literature (Safren, et al., 2001). Results demonstrated 
improvements in adherence in both conditions at two weeks posttreatment and 12-weeks 
posttreatment; however, the Life Steps condition showed faster improvements in adherence rates 
than the self-monitoring condition. This suggests that the inclusion of problem-solving and 
motivational interventions can be an effective tool at increasing medication adherence within a 
brief, single session therapeutic format. 
Limitations of Current Interventions 
Although the development of effective interventions is a promising step, several practical 






Intervention approaches that are delivered by clinical staff place additional time and expense 
burdens on health care systems and professionals that are already under heavy demands of 
patient care. To provide ideal interventions with fidelity to evidence-based approaches, 
additional burdens of training and supervision are necessary. Electronic interventions could 
overcome these barriers and aid dissemination of an efficacious, cost-effective, and high-fidelity 
intervention in the clinic setting. 
Recent studies have begun to investigate the use of electronic media (e.g., telephones, 
personal digital assistants, pagers, and web-based interventions) to improve medication 
adherence among patients with HIV and other chronic illnesses.  Cost-effective interventions 
requiring little to no additional time from health care staff that are readily accessible to a large 
portion of patients are needed among populations with a wide array of medical concerns 
including diabetes, HIV/AIDS, osteoporosis, and asthma (Bender et al., 2010; Cook, Emiliozzi, 
& McCabe, 2007; Cook, et al., 2009; Sacco, Malone, Morrison, Friedman, & Wells, 2009).   
Among these interventions, the use of messaging systems and personal digital assistants 
(PDAs) has received increasing, yet modest support.  Pagers are easily integrated into an 
individual’s daily routine and have been demonstrated to improve self-reported medication 
adherence (Erickson, Ascione, Kirking, & Johnson, 1998).  Pagers are used to send educational 
messages, support, and medication reminders to patients and do not require extensive time 
commitments by health care professionals.  Recently, a randomized controlled trial investigating 
the efficacy of pager messaging to improve adherence to HIV medication and clinical outcomes 
found that the participants receiving the pager messaging intervention displayed some clinical 






improving adherence and, in fact, demonstrated a worsening trend in adherence at six months 
(Simoni et al., 2009).  These results suggest that the pager message may not have served as a 
reminder to take the medication at the scheduled time as expected.  Further, the messages alone 
were not sufficient enough to overcome the range of factors contributing to nonadherence.  This 
demonstrates the importance of providing patients with educational and psychological 
interventions addressing these barriers to adherence. 
The use of telephone-delivered interventions has become prevalent within the literature.  
This method of intervention delivery has been supported by recent investigations that have 
utilized a psychological model to promote behavior change.  A majority of these interventions 
have been delivered by nurses trained in psychological counseling interventions based on MI and 
CBT (Cook, et al., 2007; Cook, et al., 2009; Reynolds, et al., 2008).  The use of telephone 
counseling among HIV patients has demonstrated improved rates of adherence among patients 
during the study period; however, only one study demonstrated sustained high levels of 
adherence at 32, 48, and 64 weeks post-intervention (Reynolds, et al., 2008).  Participants in this 
study already had extremely high levels of adherence at baseline (≥ 95%) in both the intervention 
and control groups which is not representative of the HIV population in general and limits 
generalizability of the results.  Cook et al. (2009) also reported increased adherence among 
participants receiving telephone counseling.  A major limitation of this study, however, was the 
lack of a comparison group that did not receive the intervention.  Further, this study had a high 
rate of attrition over the course of the intervention with almost 60% of participants lost by the six 






delivered interventions among other chronic illnesses as well (Cook, et al., 2007; Sacco, et al., 
2009). 
In addition to high rates of attrition, several concerns regarding the use of telephone-
delivered interventions have been identified.  First, although the telephone intervention is more 
cost-effective for the patient, employing registered nurses to deliver the intervention continues to 
place time constraints on the health care system and are too expensive to be widely adopted 
(Sacco, et al., 2009).  Second, program nurses have reported difficulty contacting patients, 
including disconnected telephone numbers, which pose an important concern for high levels of 
attrition from the intervention.  Current research suggests that patients who drop out of this type 
of intervention are potentially those with a higher risk of medication nonadherence and may 
benefit the most from an intervention to improve adherence (Cook, et al., 2007).  Although 
telephone-delivered interventions are limited, these studies have demonstrated that empirically 
supported psychological techniques can be successfully applied via telehealth delivery in general 
health care settings.   
 In order to compensate for the limitations of telephone counseling, the use of digital 
video on personal digital assistants (PDAs) has been presented as a means of educating patients 
about their disease and treatment and used as a medication reminding tool (Brock & Smith, 
2007; Mayhorn, Lanzolla, Wogalter, & Watson, 2005).  Brock & Smith (2007) evaluated the use 
of digital video on PDAs in a clinic setting among patients with HIV.  The video incorporated 
information aimed at increasing patient self-efficacy via education about the disease and 
treatment.  The authors reported that participants enjoyed the video and found it to be an 






indicated increased knowledge of disease, medications, and adherence behaviors after watching 
the video.  Further, self-efficacy was high post-intervention and maintained at follow-up and 
self-reported adherence to medication regimens improved.   
Although these findings are encouraging and support the implementation of technology-
assisted education in the clinical health care setting, the methodology used in this study has 
multiple limitations.  First, there was not a control group and, therefore, it is difficult to ascertain 
the effects demonstrated were not due to other confounding variables.  Second, biological 
indicators of HIV (e.g., CD4 count, viral load) were not collected; therefore, severity of disease 
may have confounded the results and objective levels of adherence were not examined.  
Additionally, the study was limited to only two clinic visits, including a follow-up at the next 
scheduled visit.  The authors did not report the timeframe between the intervention and follow-
up and did not report whether it was standardized for each participant.  This important limitation 
makes it impossible to determine if the effects seen in increased self-efficacy, adherence, and 
knowledge regarding HIV and medications were sustained.  This study does provide support for 
the feasibility and convenience of electronic educational tools in healthcare settings among 
patients with HIV and further investigation of determining the efficacy of these interventions is 
warranted.   
The use of technology-assisted education is a convenient, economical solution to the 
current limitations imposed upon health care providers.  This type of intervention requires 
minimum training and time by clinic staff and can be implemented in clinic waiting rooms.  
Additionally, this technology has the potential to be used in rural settings that lack access to 






requiring stringent medication adherence.  Developing electronic interventions based on 
currently existing empirically supported interventions may help alleviate the gap between patient 
nonadherence and the barriers that limit practitioners from delivering comprehensive, 
multifaceted effective interventions aimed at increasing adherence.  Adapting an efficacious 
program for HIV medication adherence, such as the Life Steps intervention, may be an effective 
technology-assisted educational tool. 
While the evidence for Life Steps is promising, the dissemination and adoption of the 
program is limited by the expense of professional staff, training needs, and concerns about 
treatment fidelity. The development of a brief, computerized intervention adapting the 
components of Life Steps and targeting medication adherence may reduce the already demanding 
time constraints placed on physicians and health care providers. Further, this intervention will be 
economically feasible and cost-effective and easily disseminated among patients who are at-risk 
for nonadherence, particularly patients who are initiating treatment, changing regimens, or have 
demonstrated previous failures to adhere to the regimen. This program could be included on a 
compact disc or made available via the internet allowing easy access to developing skills for 







THE PRESENT STUDY 
 The purpose of the present study is to develop an innovative computer-based adaptation 
of the evidence-based Life Steps program and evaluate the efficacy of the electronic intervention 
to enhance medication adherence and improve clinical outcomes among individuals with HIV 
via a randomized controlled trial.  By achieving these aims, the project will develop and 
rigorously test the efficacy of an intervention modality that will address the problem of 
nonadherence in an efficient and cost-effective way.   
The study will progress through three phases.  Phase One will consist of developing the 
electronic intervention and creating a script for the “electronic interviewers” to use in guiding the 
participant through the intervention.  The script for the interviewers will be developed based 
upon the Life Steps program and will strive to adhere as closely as possible to what would be 
expected of a live interviewer with expertise in the technique.  Once the script is completed, the 
material will be digitally prepared and stored for later inclusion in the interactive intervention.  
The intervention itself will be created using Adobe Presenter software, an off-the-shelf 
development application commonly used to produce distance education and training 
applications.  This software allows for presenting the intervention in an engaging, interactive and 
navigable way, while also allowing for testing participant comprehension via embedded quizzes.  
The “electronic interviewer” will participate in the Life Steps program process by walking the 
participant through each step, and providing explanatory and motivational commentary. 
In addition to the computer-based information, we will prepare a user-journal that each 
participant will use in conjunction with the program. The journal will include worksheets and 






written materials for the participant to retain after the computer interaction. The journal will also 
include a copy of the Life Steps program on a USB flash drive for subsequent review by the 
participant if needed. 
Consistent with the original Life Steps intervention, the assessment intervention itself will 
include 11 informational, problem-solving, and cognitive behavioral steps, each presented as a 
separate module. Completion of one module will direct the participant directly to the subsequent 
module. The modules are as follows: 
Step 1: Education and Introduction. This module will provide information about the 
critical role medication adherence plays in successful treatment. An understandable rationale for 
the medication regimen and adherence to the regimen will be provided. The aim of the education 
component is to increase knowledge and a sense of self-efficacy to influence their HIV treatment 
success. Patients will be reminded that, unlike other medications, antiretroviral medications are 
taken to prevent the occurrence of certain symptoms; however, they may cause negative side 
effects. Motivation for taking pills as recommended will be discussed in reference to the goal of 
blocking viral replication, reducing viral load, and preventing drug-resistant strains of HIV from 
emerging. This information will be supplemented with animated illustrations. The introduction 
will address two primary goals: (a) promote the perspective that the pills are health-protecting 
tools; and (b) introduce problem-solving for medication adherence.  
Step 2: Transportation to Appointments. This module involves problem-solving strategies 
and rehearsal techniques. The aim of this module is to address transportation issues in advance so 
patients will not miss important appointments with their health care providers. Further, brief 






distortions regarding the reactions of other people (i.e., coworkers, classmates, friends and 
family) to their recurrent appointments. 
Step 3: Obtaining Medications. Patients will develop a plan for continued access to 
medications, including payment, selection of a pharmacy, and back-up plans. This module will 
also address concerns regarding patient’s privacy and confidentiality with the pharmacist. 
Step 4: Communicating with Physicians, Nurses, and Other Members of the Treatment 
Team. Patients with HIV are frequently embarrassed about asking providers health-related 
questions. An example of an interaction between a patient and provider will be provided via a 
brief video. Brief cognitive techniques will be suggested for irrational fears about asking 
questions.  
Step 5: Coping with Side-Effects. In this module participants are asked to (a) help 
themselves pick a regimen collaboratively with their doctor to minimize side effects; (b) re-
interpret the initial side effects as signs that the medications are in their bloodstream and 
working; (c) increase the salience of the reasons for taking medications despite the side effects. 
Step 6: Formulating a Daily Medication Schedule. The goal of this module is for the 
patient to complete a detailed map of an average day of pill-taking, specifying environmental and 
other cues for pill-taking throughout the day. The participant will focus on linking medication 
doses to regular activities, disentangle a complex regimen (i.e., food restrictions with doses), and 
identify specific times that are potential risks for missing doses. The user-journal will include 
worksheets to develop a personalized daily medication schedule. 
Step 7: Storing Medications. In addition to complex schedules, many HIV regimens 






are not at home. This module focuses on problem-solving techniques and discusses additional 
interventions for storing medications including pill boxes or zip-lock bags marked with 
appropriate time, food restriction, and refrigeration information. 
Step 8: Cues for Pill-Taking. The user-journals will include a set of colored adhesive 
dots. This module illustrates how to use these dots as a cue for pill taking by placing them in 
various spots (i.e., bathroom mirror, computer at work, the receiver of a telephone) where they 
will see them. These dots are used as a cue for pill taking and to rehearse adaptive cognitions for 
adherence (i.e., “by taking my pills on time I have done my part to take care of my body”). 
Additionally, overt reminders such as linking pill taking with waking up and going to bed or 
setting alarms are discussed.  
Step 9: Guided Imagery Review of Successful Adherence in Response to Daily Cues. This 
module will help patients imaginally rehearse a full day of adherence and will include the cues 
identified in Step 8, rehearsal of adaptive cognitions, and use of relevant sensory cues to 
intensify the imagery.  
Step 10: Responses to Slips in Adherence. It is likely that at some point, the patient will 
miss a dosage. This module teaches patients how to handle slips and to avoid all-or-nothing 
thoughts. This module introduces cognitive techniques to convey the view that, although the goal 
is to maintain perfect adherence, if a lapse occurs, the best choice is to return to the regimen as 
soon as possible. 
Step 11: Review of Procedures. To help patients remember the strategies discussed, this 






such as questions to ask the physician, purchasing a refrigerator bag or pill box, purchasing an 
alarm watch, or placing the colored dots. 
Phase Two will consist of implementing a randomized trial with HIV patients who are 
either new patients or at-risk for nonadherence to investigate the effectiveness of the new 
intervention. Patients will be recruited through a community health center that serves primarily 
patients living with HIV.  Participants who meet the screening criteria will be randomly assigned 
(by computer generated number) to one of the following conditions: (1) Treatment as usual 
(TAU) or (2) TAU + Life Steps electronic intervention. We estimate completion of the 
intervention to take approximately 90-120 minutes. 
Immediately after the intervention, participants will complete a brief program satisfaction 
questionnaire to rate their experience with the intervention, self-efficacy to properly take and 
manage their medications, commitment to adhere to medication regimens, and to indicate their 
current intentions to make any changes in their medication-taking behavior. At one, three, and 
six months, participants will be re-contacted and will complete a brief interview to indicate their 
current levels of adherence and problems experienced in the last month. Each interview should 
take approximately 30 minutes. 
Phase Three will be devoted to completing all follow-up interviews, and data compilation 
and analysis. The effects of the intervention will be evaluated by the following hypotheses: 
 Hypothesis 1. Participants in the Life Steps electronic intervention will report higher self-
efficacy and commitment to maintain adherence to their medical regimens as compared to those 






 Hypothesis 2. Participants in the Life Steps electronic intervention will demonstrate 
greater self-reported medication adherence than those in the TAU condition. 
 Hypothesis 3. Participants in the Life Steps electronic intervention condition will 
demonstrate superior viral load and immunologic outcomes (decreased viral load and increased 
CD4 count) compared to those in the TAU condition. 
 Hypothesis 4. Participants in the Life Steps electronic intervention condition will report 
high satisfaction with the intervention.  
METHODOLOGY 
Participant Recruitment and Selection 
 One-hundred patients (50 participants in each condition) with HIV who currently are 
prescribed an antiretroviral medication regimen will be recruited for this study from the Internal 
Medicine Specialty Services in Tulsa, Oklahoma, an outpatient clinic at the Oklahoma State 
University Center for Health Sciences that serves primarily patients living with HIV.  Patients 
who are (a) infected with HIV, (b) over the age of 18, (c) currently prescribed a Highly Active 
Antiretroviral Therapy (HAART) regimen, (d) prescribed a drug regimen for the first time, 
changing regimens, or report adherence below 95%, and (e) agree to three brief follow-up 
interviews over the course of one year, will be invited to participate in the study.        
Measures 
 Participants who meet the inclusion criteria will complete a questionnaire (see Appendix) 
including six measures assessing demographic information, adherence to HIV medications 
(AACTG Medication Adherence Questionnaire), self-efficacy to adhere to HIV regimen (HIV 






(McGill Quality of Life Questionnaire), and intervention satisfaction (The Program Satisfaction 
Questionnaire).   
 Demographics Questionnaire.  Information regarding gender, age, and ethnicity will be 
gathered using the demographics questionnaire.  Additional information regarding the 
participants’ current living situation, marital status, sexual orientation, and educational 
attainment will also be collected. 
 AACTG Medication Adherence Questionnaire. Self-reported adherence to HIV 
medications will be assessed using the AACTG Medication Adherence Questionnaire (M. A. 
Chesney, et al., 2000). This instrument was developed by the Adult AIDS Clinical Trials Group 
(AACTG) and is a five-item self-report measure that has been used extensively in the United 
States and internationally to assess adherence to antiretroviral medications (Reynolds et al., 
2007).  This measure queries patients on the number of doses he or she has missed of each 
medication during each of the last four days.  Additionally, other adherence behaviors are 
assessed such as following specified instructions, missing doses on the weekend, and how 
closely the patient followed the specific schedule.  To assess adherence, researchers have 
frequently analyzed data collected with the first item of the questionnaire only (“How many 
doses did you miss yesterday/2 days ago/3 days ago/4 days ago”) by averaging these responses 
and excluding the other four questionnaire items.   
Reynolds, Sun, Nagaraja, Gifford, Wu & Chesney (2007) examined the psychometric 
properties of each item and compared the common approach of averaging data from the first item 
to alternative methods using principal component analysis and the entire questionnaire.  The 






adherence; however, the strength of measure of adherence improved with inclusion of the 
remaining items of the questionnaire.  The authors presented a formula for calculating an 
adherence index obtained via principal component analyses and weighted each of the items.  
This formula, when compared to the 4-day recall only item, was less skewed and compared 
favorably with two objective measures of adherence (MEMS electronic monitoring system and 
plasma HIV RNA).  The AACT Medication Adherence Questionnaire has demonstrated good 
reliability (Cronbach’s alpha = .80). 
 HIV Treatment Adherence Self-Efficacy Scale (HIV-ASES). Self-efficacy for adherence to 
HIV medications will be assessed using the HIV-ASES (Johnson et al., 2007).  The HIV-ASES 
is a 12-item scale of patient confidence in their ability to carry out behaviors related to adhering 
to medication regimens.  Responses range from 1 (“cannot do it at all”) to 10 (“completely 
certain can do it”).  Item scores are averaged with higher scores indicating higher adherence self-
efficacy.  Analysis of the HIV-ASES has revealed robust internal consistency (.90) and 
reliability (.91). 
 Commitment to Adhere to HIV Medication Regimens. This item was developed for the 
purposes of this study and consists of a single question addressing the participant’s level of 
commitment to adhere to the currently prescribed antiretroviral medication regimen. Responses 
range from 0 (“not committed at all”) to 10 (“completely committed”) with high scores 
demonstrating higher levels of commitment to adherence. 
McGill Quality of Life (MQOL). Quality of life will be assessed using the McGill Quality 
of Life questionnaire (Cohen, Hassan, Lapointe, & Mount, 1996).  This instrument is a 16-item 






existential well-being, and support; each item is assessed on a 0-10 point scale.  The MQOL has 
been widely used in research for people with life- threatening illnesses and has been translated 
and validated in a variety of languages.  The MQOL has demonstrated good internal validity 
(0.74-0.92) and test-retest reliability (0.70) (Cohen et al., 1997). 
Clinical outcomes. Medical records for each subject will be reviewed for the most recent 
laboratory test results of CD4
+
 cell counts, viral load, and occurrence of opportunistic infections. 
 Program Satisfaction Questionnaire. This questionnaire was developed for the purposes 
of this study to address the level of satisfaction with the intervention.  This questionnaire consists 
of eight items assessing level of agreement or disagreement with the statement, such as “I would 
recommend this program to a friend” and “I learned new things from the program.” 
Treatment Procedures 
 Participants who meet the general screening criteria will be randomly assigned (by 
computer generated number) to one of two groups: (1) Treatment as usual (TAU) or (2) TAU + 
Life Steps electronic intervention.  It is estimated that completion of the intervention will take 
approximately 90-120 minutes. 
Immediately following the intervention, participants will complete a brief program 
satisfaction questionnaire to rate their experience with the intervention, self-efficacy to properly 
take and manage their medications, commitment to adhere to medication regimens, and to 
indicate their current intentions to make any changes in their medication-taking behavior. At 
three, six, and twelve months, participants will be re-contacted and will complete a brief 
interview to indicate their current levels of adherence and problems experienced in the last 
















 A randomization check will be conducted to verify that there are no statistically 
significant differences between the two conditions on key baseline variables.  Specifically, chi-
square tests will be conducted to assess for any significant differences with regard to age, gender, 
ethnicity, current living situation, marital status, sexual orientation, educational attainment, and 
the presence of an opportunistic infection.  A t-test will assess for meaningful differences with 
regard to viral load and CD4 cell count   
Primary Analyses 
Hypothesis One. Participants in the Life Steps electronic intervention condition will 
report high satisfaction with the intervention.  Means and standard deviations for a participant 
satisfaction measure will be evaluated and compared to the scale anchors to determine if the 
level of satisfaction is relatively high or low.      
Hypothesis Two.  Participants in the Life Steps program will report higher self-efficacy 
and commitment to maintain adherence to their medical regimens as compared to those in the 
TAU condition.  Immediate post-intervention scores on measures of self-efficacy for treatment 
adherence and commitment to adherence will be calculated for all participants. Differences 
between groups will be evaluated with t-tests of the group means, assuming there are not 
significant differences in demographic variables at baseline. If significant demographic variables 
exist, they will be included as covariates in ANCOVA analyses of between group means.  If the 






participants in the Life Steps condition reporting higher scores of self-efficacy (HIV-ASES) and 
commitment to adherence.      
Hypothesis Three.  Participants in the Life Steps electronic intervention condition will 
demonstrate greater self-reported medication adherence than those in the TAU condition.  
Between-group differences in self-reported adherence will be evaluated at each follow-up time 
point with t-tests of group means (or ANCOVA if necessary, as above). Time (Post-intervention 
and 3-month follow-up)  Treatment (TAU, Life Steps) interaction effects in mixed model 
ANOVAs will also be evaluated to examine differences in patterns of change in adherence over 
time between the two groups.  A significant difference on measures of adherence, with the Life 
Steps condition demonstrating higher scores on the ACTG Medication Adherence Questionnaire 
would confirm this hypothesis.  
Hypothesis Four.  Participants in the Life Steps electronic intervention condition will 
demonstrate superior viral and immunologic outcomes (viral load and CD4 count) compared to 
those in the TAU condition.  Between-group differences in CD4 count and viral load will be 
evaluated at each follow-up time point with t-tests of group means (or ANCOVA if necessary, as 
above). Time (Post-intervention and 3-month follow-up)  Treatment (TAU, Life Steps) 
interaction effects in mixed model ANOVAs will also be evaluated to examine differences in 
patterns of change in viral and immunologic outcomes over time between the two groups.  A 
significant difference on measures of CD4 count and viral load, with the Life Steps condition 
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Participant ID# ___________ 
Date of Birth: ____________ 
 
Gender: □ Male  □ Female   
Ethnicity:   
□ Caucasian or White    □ Hispanic or Latino  □ Biracial/Mixed 
□ African-American or Black  □ Asian   □ American Indian  
□ Pacific Islander   □Other _________________ □ Prefer not to respond 
 
Educational Attainment: 
□ Some High School  □ Some College  □ Master’s-level  
□ High School     □ College     □ Doctoral-level 
□ Prefer not to respond 
 
Marital Status: 
□ Never married  □ Married   □ Divorced   
□ Remarried   □ Separated   □ Common Law  
□ Domestic Partnership  □ Widowed   □ Live w/ same sex partner  
□ Live w/ opposite sex partner □ Prefer not to respond 
 
Housing Status: 
□ Your house/apt □ Someone else’s house/apt  □ Transitional housing  
□ On the street  □ Institution ≤ 30 days   □ Institution > 30days   
 
Self-identified Sexual Orientation: 
□ Bisexual   □ Gay/lesbian    □ Heterosexual  
□ Undecided   □ Prefer not to respond 
 
What is/are the most likely way/s that you became infected with HIV? 
□ Sex with a man who was HIV+   
□ Sex with a woman who was HIV+ 
□ Shared needles with someone who was HIV+   
□ Blood transfusion or other medical procedure  
□ Don’t know      
□ Other (needle stick at work, etc.) _________________ 










HIV Treatment Adherence Self-Efficacy Scale (HIV-ASES) 
 
I am going to ask you about situations that could occur during your treatment for HIV.  Treatment can 
involve different things for different people.  Sometimes, this might refer to taking medications, and other 
times it could refer to other things that you do to deal with HIV such as diet and exercise or taking 
vitamins.  So, in these questions, when I ask you about your “treatment” or your “treatment plan,” I am 
talking not only about any medications that you might be taking for HIV, but also other things that make 
up your self-care. 
 
For the following questions I will ask you to tell me in the past month, including today, how confident 
you have been that you can do the following things.  Use this response ranging from 0 (“cannot do at all”) 




0      5             10  
Cannot do at all       Moderately            Completely  
certain can do                certain can do 
 
In the past month, how confident have you been that you can: 
1. Stick to your treatment plan even when side effects begin to interfere with daily activities? 
2. Integrate your treatment into your daily routine? 
3. Integrate your treatment into your daily routine even if it means taking medication or doing other 
things in front of people who don’t know that you are HIV-infected? 
4. Stick to your treatment schedule even when your daily routine is disrupted? 
5. Stick to your treatment schedule when you aren’t feeling well? 
6. Stick to your treatment schedule when it means changing your eating habits? 
7. Continue with your treatment even if doing so interferes with your daily activities? 
8. Continue with the treatment plan your physician prescribed even if your T-cells drop significantly 
in the next three months? 
9. Continue with your treatment even when you are feeling discouraged about your health? 
10. Continue with your treatment even when getting to your clinic appointments is a major hassle? 
11. Continue with your treatment even when people close to you tell you that they don’t think that it 
is doing any good? 
12. Get something positive out of your participation in treatment, even if the medication you are 








ACTG Medication Adherence Questionnaire 
 
This questionnaire asks about your HIV study medications that you took over the last four days. 
Most people with HIV have many pills to take at different times during the day. 
Many people find it hard to always remember their pills: 
 Some people get busy and forget to carry their pills with them. 
 Some people find it hard to take their pills according to all the instructions, such as “with meals,” 
or “on an empty stomach,”“every 8 hours,”“with plenty of fluids.” 
 Some people decide to skip doses to avoid side effects or to just not be taking pills that day. 
 
We need to understand how people with HIV are really doing with their pills. Please tell us what you are 
actually doing. Don’t worry about telling us that you don’t take all your pills. We need to know what is 
really happening, not what you think we “want to hear.” 
A. This section of the questionnaire asks about the study medications that you may have 
missed taking over the last four days. Please complete the following table by filling in the 
boxes below. 
 
IF YOU TOOK ONLY A PORTION OF A DOSE ON ONE OR MORE OF THESE DAYS, 




Names of your 
anti-HIV drugs 







(2 days ago) 
Step 4 
 
3 days ago 
Step 5 
 
4 days ago 
 ____ doses ____ doses ____ doses ____ doses 
 ____ doses ____ doses ____ doses ____ doses 
 ____ doses ____ doses ____ doses ____ doses 
 ____ doses ____ doses ____ doses ____ doses 
 ____ doses ____ doses ____ doses ____ doses 
 ____ doses ____ doses ____ doses ____ doses 








If you only took a portion of a dose on one or more of these days, please report the dose(s) as being 
missed. 
 
B.  During the past 4 days, on how many days have you missed taking all your doses? 
 
□ None    □ Three days 
□ One day   □ Four days 
□ Two days 
 
C.  Most anti-HIV medications need to be taken on schedule, such as “2 times a day” or 
     “3 times a day” or “every 8 hours.”  How closely did you follow your specific schedule  
     over the last four days? 
 
□ Never  □ Some of the time  □ About half of the time  
□ Most of the time  □ All of the time 
 
D.  Do any of your anti-HIV medications have special instructions, such as “take with  
      food” or “on an empty stomach” or “with plenty of fluids?” 
 
□ Yes    □ No 
 
 If yes, how often did you follow those special instructions over the last four days?  
 
□ Never  □ Some of the time  □ About half of the time 
□ Most of the time  □ All of the time 
 
E. Some people find that they forget to take their pills on the weekend days. Did you miss   
     any of your anti-HIV medications last weekend— last Saturday or Sunday? 
 
 □ Yes    □ No 
 
F. When was the last time you missed any of your medications? Check one. 
• 
□ Within the past week 
• □ 1-2 weeks ago 
• □ 2-4 weeks ago 
• □ 1-3 months ago 
□ More than 3 months ago 
• □ Never skip medications or not applicable 
 
If you Never skip medications, please skip Section G. Otherwise, please continue by answering the next 









G. People may miss taking their medications for various reasons. Here is a list of 
     possible reasons why you may miss taking your medications. How often have you  
     missed taking your medications because you: (Circle one response for each question.) 
 
 
 Never Rarely Sometimes Often 
 










2. Were busy with other things? 0 1      2 3 
 
3. Simply forgot? 0 1      2 3 
 
4. Had too many pills to take? 0 1      2 3 
 
5. Wanted to avoid side effects? 0 1       2 3 
 
6. Did not want others to notice you 
taking medication? 
0 1       2 3 
 
 
7. Had a change in daily routine? 0 1      2 3 
 
8. Felt like the drug was toxic/harmful? 0 1      2 3 
 
 
9. Fell asleep/slept through dose time? 0 1      2 3 
 
 
10. Felt sick or ill? 0 1      2 3 
 
11. Felt depressed/overwhelmed? 0 1      2 3 
 
12. Had problems taking pills at specified 
times (with meals, on empty stomach, 
etc.) 




13. Ran out of pills? 0 1      2 3 
 









Confidence and Commitment Measure 
 
How CONFIDENT are you that you can maintain 100% adherence with taking your HIV 
medications as prescribed? 
 
o o o o o o o o o o  
        Not at all                   Totally 




How COMMITTED are you to taking your HIV medications as prescribed 100% of the time 
(taking the right doses, on time, and every day)? 
 
o o o o o o o o o o  
        Not at all                   Totally 







PROGRAM SATISFACTION QUESTIONNAIRE 
 
INSTRUCTIONS 
Please rate your level of agreement with each of the following statements to indicate your level 
of satisfaction with the program you just completed.  Circle one response for each item that best 
represents your level of agreement. 
 
1. I would recommend this program to a friend. 
Strongly 
Disagree 
Disagree Uncertain Agree 
Strongly 
Agree 
2. The interview was thorough and complete. 
Strongly 
Disagree 
Disagree Uncertain Agree 
Strongly 
Agree 
3. The program seemed well-organized. 
Strongly 
Disagree 
Disagree Uncertain Agree 
Strongly 
Agree 
4. The program was not confrontational. 
Strongly 
Disagree 
Disagree Uncertain Agree 
Strongly 
Agree 
5. The program made me think about my 
adherence to HIV medications. 
Strongly 
Disagree 
Disagree Uncertain Agree 
Strongly 
Agree 
6. I learned new things from the program. 
Strongly 
Disagree 
Disagree Uncertain Agree 
Strongly 
Agree 
7. What did you find most useful about the program? 
 
 


















































Title: Electronic Intervention for HIV Medication Adherence 
 
Investigators: 
Thad R. Leffingwell, Ph.D., Oklahoma State University, Department of Psychology 
Kasey R. Claborn, M.S., Oklahoma State University, Department of Psychology 
Johnny R. Stephens, Pharm. D., Oklahoma State University-Center for Health Sciences, 
Department of Internal Medicine 
 
A. Specific Aims 
Non-adherence to prescribed medication regimens among HIV patients is a serious public 
health concern. Unlike other chronic illnesses, effective HIV treatment requires stringent 
adherence rate of 95% or better to maximize the chances of treatment success and reduce the 
likelihood of developing drug resistant strains of HIV. Rates of non-adherence range from 31-
70% among patients with HIV and tend to decline over time.(Ickovics, et al., 2002; Johnson, et 
al., 2003; Paterson, et al., 2000) Recent developments in intervention have found targeted 
intervention efforts using cognitive behavior therapy and motivational interviewing techniques to 
be effective at increasing adherence rates among patients with HIV(Parsons, et al., 2007). The 
effects of these interventions have proven superior to the long-standing educational and self-
monitoring approaches.(Julius, et al., 2009)
  
Although the development of effective interventions is a promising step, several practical 
barriers limit the likelihood of widespread dissemination and adoption of these methods. 
Intervention approaches that are delivered by clinical staff place additional time and expense 
burdens on health care systems and professionals that are already under heavy demands of 
patient care. To provide ideal interventions with fidelity to evidence-based approaches, 
additional burdens of training and supervision are necessary. Electronic, computer-based 
interventions could overcome these barriers and aid dissemination of an efficacious, cost-
effective, and high-fidelity intervention in the clinic setting. The specific aims of the proposed 
project are: 
1. Develop an innovative computer-based electronic adaptation of the evidence-based 
Life Steps program to enhance HIV medication adherence. 
2. Evaluate the efficacy of the electronic intervention to enhance medication adherence 






By achieving these aims, the project will develop and rigorously test the efficacy of an 
intervention modality that will address the problem of nonadherence in an efficient and cost-
effective way.  
B. Research Design and Methods 
The electronic intervention will be developed and pilot tested. We will assemble a battery 
of measures and plan the intervention, including creating a script for the “electronic 
interviewers” to use in guiding the participant through the intervention. The script for the 
interviewers will be developed based upon the empirically validated Life-Steps program
6
, and 
will strive to adhere as closely as possible to what would be expected of a live interviewer with 
expertise in the technique. The intervention itself will be developed using Adobe Presenter 
software, an off-the-shelf development application commonly used to produce distance 
education and training applications. This software allows for presenting the intervention in an 
engaging, interactive and navigable way, while also allowing for testing participant 
comprehension via embedded quizzes. The “electronic interviewer” will participate in the Life-
Steps program process by walking the participant through each step, and providing explanatory 
and motivational commentary.  
In addition to the computer-based information, we will prepare a user-journal that each 
participant will use in conjunction with the program. The journal will include worksheets and 
written resources to supplement the computer information and provide the user with some 
written materials for the participant to retain after the computer interaction. The journal will also 
include a copy of the Life Steps program on a compact disc for subsequent review by the 
participant if needed. 
Consistent with the original Life-Steps intervention, the assessment intervention itself will 
include 10 informational, problem-solving, and cognitive behavioral steps, each presented as a 
separate module. Completion of one module will direct the participant directly to the subsequent 
module. The modules are as follows: 
Step 1: Education and Introduction. This module will provide information about the 
critical role medication adherence plays in successful treatment. An understandable rationale for 
the medication regimen and adherence to the regimen will be provided. The aim of the education 
component is to increase knowledge and a sense of self-efficacy to influence their HIV treatment 
success. Patients will be reminded that, unlike other medications, antiretroviral medications are 
taken to prevent the occurrence of certain symptoms; however, they may cause negative side 
effects. Motivation for taking pills as recommended will be discussed in reference to the goal of 
blocking viral replication, reducing viral load, and preventing drug-resistant strains of HIV from 
emerging. This information will be supplemented with animated illustrations. The introduction 
will address two primary goals: (a) promote the perspective that the pills are health-protecting 






Step 2: Transportation to Appointments. This module involves problem-solving strategies 
and rehearsal techniques. The aim of this module is to address transportation issues in advance so 
patients will not miss important appointments with their health care providers. Further, brief 
cognitive-restructuring and problem-solving approaches can be employed for cognitive 
distortions regarding the reactions of other people (i.e., coworkers, classmates, friends and 
family) to their recurrent appointments. 
Step 3: Obtaining Medications. Patients will develop a plan for continued access to 
medications, including payment, selection of a pharmacy, and back-up plans. This module will 
also address concerns regarding patient’s privacy and confidentiality with the pharmacist. 
Step 4: Communicating with Physicians, Nurses, and Other Members of the Treatment 
Team. Patients with HIV are frequently embarrassed about asking providers health-related 
questions. An example of an interaction between a patient and provider will be provided via a 
brief video. Brief cognitive techniques will be suggested for irrational fears about asking 
questions.  
Step 5: Coping with Side-Effects. In this module participants are asked to (a) help 
themselves pick a regimen collaboratively with their doctor to minimize side effects; (b) re-
interpret the initial side effects as signs that the medications are in their bloodstream and 
working; (c) increase the salience of the reasons for taking medications despite the side effects. 
Step 6: Formulating a Daily Medication Schedule. The goal of this module is for the 
patient to complete a detailed map of an average day of pill-taking, specifying environmental and 
other cues for pill-taking throughout the day. The participant will focus on linking medication 
doses to regular activities, disentangle a complex regimen (i.e., food restrictions with doses), and 
identify specific times that are potential risks for missing doses. The user-journal will include 
worksheets to develop a personalized daily medication schedule. 
Step 7: Storing Medications. In addition to complex schedules, many HIV regimens 
require some medications to be refrigerated which may pose a problem for patients when they 
are not at home. This module focuses on problem-solving techniques and discusses additional 
interventions for storing medications including pill boxes or zip-lock bags marked with 
appropriate time, food restriction, and refrigeration information. 
Step 8: Cues for Pill-Taking. The user-journals will include a set of colored adhesive 
dots. This module illustrates how to use these dots as a cue for pill taking by placing them in 
various spots (i.e., bathroom mirror, computer at work, the receiver of a telephone) where they 
will see them. These dots are used as a cue for pill taking and to rehearse adaptive cognitions for 
adherence (i.e., “by taking my pills on time I have done my part to take care of my body”). 
Additionally, overt reminders such as linking pill taking with waking up and going to bed or 






Step 9: Responses to Slips in Adherence. It is likely that at some point, the patient will 
miss a dosage. This module teaches patients how to handle slips and to avoid all-or-nothing 
thoughts. This module introduces cognitive techniques to convey the view that, although the goal 
is to maintain perfect adherence, if a lapse occurs, the best choice is to return to the regimen as 
soon as possible. 
Step 10: Review of Procedures. To help patients remember the strategies discussed, this 
module reviews the previous steps and provides feedback to the client regarding any action items 
such as questions to ask the physician, purchasing a refrigerator bag or pill box, purchasing an 
alarm watch, or placing the colored dots. 
Evaluation Methodology 
We will implement a randomized trial with HIV patients who are either new patients or 
at-risk for nonadherence to investigate the effectiveness of the new intervention. Patients with 
HIV who currently are prescribed an antiretroviral medication regimen will be recruited through 
the Internal Medicine Specialty Services which is an outpatient clinic through Oklahoma State 
University Center for Health Sciences that serves primarily patients living with HIV. To be 
included in the study, patients must be (a) infected with HIV, (b) over the age of 18, (c) currently 
prescribed a Highly Active Antiretroviral Therapy (HAART) regimen,  regimen for the first 
time, changing regimens, or report adherence below 95%, and (d) agree to three brief follow-up 
interviews over the course of one year. Participants will be excluded from the study if they 
present with a physical impairment that would prevent them from successfully completing the 
computer-based program (e.g., blind, deaf); however, if an individual with these impairments 
presents for the study, the authors will adapt the computer-based program to meet the needs of 
the individual (i.e., add captions to the program for someone who is deaf) and allow them to 
complete the program.  Additionally, potential participants who report being actively psychotic 
will be ineligible from the study.   Participants who meet the screening criteria will be randomly 
assigned (by computer generated number) to one of the following conditions: (1) Treatment as 
usual (TAU; N = 50) or (2) TAU + Life Steps electronic intervention (N = 50). We estimate 
completion of the intervention to take approximately 35-45 minutes. 
Immediately after providing written consent to participate in the study, participants will 
complete a brief questionnaire (see Appendix C) including six measures assessing demographic 
information, adherence to HIV medications (AACTG Medication Adherence Questionnaire), 
self-efficacy to adhere to HIV regimen (HIV Treatment Adherence Self-Efficacy Scale), 
commitment to adhere to HIV regimen, quality of life (McGill Quality of Life Questionnaire), 
and intervention satisfaction (The Program Satisfaction Questionnaire).   
Demographics Questionnaire.  Information regarding gender, age, and ethnicity will be 
gathered using the demographics questionnaire.  Additional information regarding the 
participants’ current living situation, marital status, sexual orientation, and educational 






AACTG Medication Adherence Questionnaire. Self-reported adherence to HIV 
medications will be assessed using the AACTG Medication Adherence Questionnaire (M. A. 
Chesney, et al., 2000). This instrument was developed by the Adult AIDS Clinical Trials Group 
(AACTG) and is a five-item self-report measure that has been used extensively in the United 
States and internationally to assess adherence to antiretroviral medications (Reynolds, et al., 
2007).  This measure queries patients on the number of doses he or she has missed of each 
medication during each of the last four days.  Additionally, other adherence behaviors are 
assessed such as following specified instructions, missing doses on the weekend, and how 
closely the patient followed the specific schedule.  The AACT Medication Adherence 
Questionnaire has demonstrated good reliability (Cronbach’s alpha = .80). 
HIV Treatment Adherence Self-Efficacy Scale (HIV-ASES). Self-efficacy for adherence to 
HIV medications will be assessed using the HIV-ASES (Johnson, et al., 2007).  The HIV-ASES 
is a 12-item scale of patient confidence in their ability to carry out behaviors related to adhering 
to medication regimens.  Responses range from 1 (“cannot do it at all”) to 10 (“completely 
certain can do it.”  Item scores are averaged with higher scores indicating higher adherence self-
efficacy.  Analysis of the HIV-ASES has revealed robust internal consistency (.90) and 
reliability (.91). 
Commitment to Adhere to HIV Medication Regimens. This item was developed for the 
purposes of this study and consists of a single question addressing the participant’s level of 
commitment to adhere to the currently prescribed antiretroviral medication regimen. Responses 
range from 0 (“not committed at all”) to 10 (“completely committed”) with high scores 
demonstrating higher levels of commitment to adherence. 
HIV Medication Readiness Scale (HMRS). Readiness to successfully start and adhere to 
HIV medications will be assessed using the HIV Medication Readiness Scale (Balfour et al., 
2007).  The HMRS is a brief 10-item questionnaire that assesses the level of readiness and 
likelihood of adhering to medications in people living with HIV.  This measure has demonstrated 
high internal consistency (alpha=.90) and test-retest reliability (r=.83). 
McGill Quality of Life (MQOL). Quality of life will be assessed using the McGill Quality 
of Life questionnaire (Cohen, et al., 1996).  This instrument is a 16-item scale that assesses 
quality of life in four domains: physical well-being, psychological well-being, existential well-
being, and support; each item is assessed on a 0-10 point scale.  The MQOL has been widely 
used in research for people with life- threatening illnesses and has been translated and validated 
in a variety of languages.  The MQOL has demonstrated good internal validity (0.74-0.92) and 
test-retest reliability (0.70) (Cohen, et al., 1997). 
Simple Screening Instrument for AOD Abuse (SSI-AOD). The Simple Screening 
Instrument for AOD abuse (Winters & Zenilman, 1994) will be used to assess alcohol and other 
drug use within the previous 6 months.  The SSI-AOD is a 16-item self-report measure 
consisting of 16 dichotomous (yes/no) items.  Domains measured by the instrument include: (1) 






consequences; (4) problem recognition; and (5) tolerance and withdrawal. The SSI-AOD has 
demonstrated good test-retest reliability (r = .90).    
Center for Epidemiologic Studies Depression Scale (CES-D). The Center for 
Epidemiologic Studies Depression Scale (CES-D; Radloff, 1977) is a brief, 20-item self-report 
instrument that measures the presence and severity of symptoms of depression in the general 
population.  Responses for each of the items are on a Leikert scale from 0, “rarely or none of the 
time” to 3, “most or all of the time.”  Responses are summed to obtain total scores from 0 to 60.  
Scores of 16 or above indicate high depressive symptoms without a clinical diagnosis.  The CES-
D has demonstrated high internal consistency ( = .85) in a general population sample and even 
higher internal consistency ( = .90) in a patient sample (Radloff, 1977).  It also has 
demonstrated good concurrent validity (r = .51 to .61) with scales designed to measure 
symptoms of depression.  This measure will be included to assess symptoms of depression. 
Clinical outcomes. Medical records for each subject will be reviewed for the most recent 
laboratory test results of CD4+ cell counts, viral load, and occurrence of opportunistic infections.  
These records will be reviewed three weeks after baseline assessment and within two weeks after 
each follow-up point. This time frame will allow the investigators to access the most recent 
clinical data relevant to the time point. 
Program Satisfaction Questionnaire. This questionnaire was developed for the purposes 
of this study to address the level of satisfaction with the intervention.  This questionnaire consists 
of eight items assessing level of agreement or disagreement with the statement, such as “I would 
recommend this program to a friend” and “I learned new things from the program.” 
At one, three, and six months, participants will be re-contacted in person at regularly 
scheduled clinic visits or via telephone and will complete a brief interview to indicate their 
current levels of adherence and problems experienced in the last month. Each interview should 
take approximately 20 minutes. Participation in this research study is voluntary. The participant 
is free to refuse to participate in any procedure and to refuse to answer any question at any time, 
and is free to withdraw his or her consent, and to withdraw from the research at any time without 
penalty. 
Given the sensitive nature of the information being collected in this study, special 
precautions are planned to help ensure anonymity for all participants. First, a random, unique 
subject identification number will be created for each participant in the study. A key connecting 
all of the identification numbers with participant names will be maintained on a secure list, 
separate from any participant data, and stored in a locked filing cabinet in a locked room to 
which only members of the research team will have access. Second, all records from this study 
will be kept confidential to the extent allowable by law, and several measures will be taken to 
minimize the likelihood that this confidentiality will be compromised. Computerized data will be 
maintained on a password-protected computer in a password-protected file accessible only by 
members of the research team. Results of this study will be reported in aggregate form. In other 






collection will be observed by research oversight staff responsible for safeguarding the rights and 
wellbeing of people who participate in research. All non-computerized records will be kept in a 
locked filing cabinet in a locked room separate from any identifying information. 
There are several potential risks from participating in this study. First, some people may 
experience some minor temporary emotional discomfort when responding to questions about 
their use of HIV medications.  Participation in this study may also cause some people to reflect 
on important life choices and experiences.  Information about professional services available to 
the participant in the community will be made available upon request in addition to the support 
and assistance already available to every patient within the clinic.  Additionally, potential 
benefits from participating in this study need to be acknowledged.  First, many participants learn 
important information about themselves and their behavior related to taking anti-HIV 
medications as a result of involvement in research that may help them to make decisions to 
reduce their risk for developing strands of HIV that do not respond to treatment and improve 
their health.  
Participants in this study will be compensated for completion of each assessment point. 
Participants will be entered in a lottery to win a portable DVD player for completing the initial 
session and will receive $5 for completing each of three follow-up interviews for a total of $15 at 
the end of the study. 
The effects of the intervention will be evaluated using a number of statistical analyses, 
described as follows by hypothesis: 
1. Participants in the Life Steps electronic intervention condition will report high 
satisfaction with the intervention. 
Means and standard deviations for a participant satisfaction measure will be evaluated 
and compared to the scale anchors to determine if the level of satisfaction is relatively 
high or low. 
2. Participants in the Life Steps program will report higher self-efficacy and 
commitment to maintain adherence to their medical regimens as compared to those in 
the TAU condition. 
Immediate post-intervention scores on measures of self-efficacy for treatment 
adherence and commitment to adherence will be calculated for all participants. 
Differences between groups will be evaluated with t-tests of the group means, 
assuming there are not significant differences in demographic variables at baseline. If 
significant demographic variables exist, they will be included as covariates in 
ANCOVA analyses of between group means. 
3. Participants in the Life Steps electronic intervention condition will demonstrate 






Between-group differences in self-reported adherence will be evaluated at each 
follow-up time point with t-tests of group means (or ANCOVA if necessary, as 
above). Time  Treatment interaction effects in mixed model ANOVAs can also be 
evaluated to examine differences in patterns of change in adherence over time 
between the two groups. 
4. Participants in the Life Steps electronic intervention condition will demonstrate 
superior viral and immunologic outcomes (viral load and CD4 count) compared to 
those in the TAU condition. 
Between-group differences in self-reported adherence will be evaluated at each 
follow-up time point with t-tests of group means (or ANCOVA if necessary, as 
above). Time  Treatment interaction effects in mixed model ANOVAs can also be 
evaluated to examine differences in patterns of change in adherence over time 
between the two groups. 
Statistical Power and Estimated Sample Size 
We estimated our sample size based upon expectations of patient flow in our partner 
clinic. Based upon this sample size (n=100), we utilized the G*Power program to estimate the 
size of effect we should be able to detect at α = .05 and statistical power of at least .80. With a 
sample size of 100, our study should be able to reliably detect an effect size of .57, or a moderate 
effect. An effect of this size (a little more than one half of a standard deviation difference) would 
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Additional Analyses with Alternative Missing Data Options 
 
 Missing data is a common problem in HIV clinical trials. In this study the attrition rate 
from baseline to one-month follow-up was 25% which is within the expected range for clinical 
trials with this population (Amico, Harman, & O’Grady, 2009). Excluding participants who fail 
to complete the entire study, however, may yield biased results. A variety of methods can be 
used to analyze outcomes with missing data points. In addition to using regression imputation as 
cited in the above manuscript, analyses were also conducted using the last observation carried 
forward and mean imputation methods. Further, analyses were examined excluding participants 
who did not complete the study (non-completers). Results and conclusions from each of the 
analytical methods are discussed. 
Primary Analyses Utilizing the Last Observation Carried Forward Method 
The last observation carried forward (LOCF) method of handling missing data points 
imputes values based on the existing data. This method has been widely used in longitudinal 
clinical trials; however, recent literature suggests that it provides biased estimates of potential 
effects of the treatment. Several advantages to using this method include: (1) minimization of 
participants excluded from analyses; and (2) allow examination of trends over time from baseline 
to follow-up. 
Treatment Self-Efficacy 
Immediate post-intervention scores on the measure of self-efficacy (HIV-ASES) for 
treatment adherence were calculated for all participants. For those who were missing data points 






that participant’s one-month follow-up data point. Time  Condition interaction effects in mixed 
model ANOVAs were examined and failed to demonstrate a significant difference between the 
two conditions F(1, 87) = 2.93, p = .09, 
2
=.03. Between-group differences in self-efficacy were 
evaluated at the one-month follow-up time point with t-tests of group means. Results failed to 
reach significance t(87) = 1.63, p = .11. Based on the LOCF method of analysis, these results 
suggest the intervention did not have a significant effect on self-efficacy at one-month follow-up. 
Adherence 
Adherence scores were calculated for all participants using self-reported 4-day recall 
data. For those who were missing data points at one-month follow-up, baseline data for each 
participant was imputed for that participant’s one-month follow-up data point. Time  
Condition interaction effects in mixed model ANOVAs were evaluated to examine differences in 
patterns of change in adherence over time between the two groups.  Although approaching 
significance, the interaction term failed to demonstrate a statistically significant difference in the 
pattern of change in adherence over time between conditions F(1, 92) = 3.47, p=.07, 
2
=.04. 
Between-group differences in adherence were evaluated at baseline and one-month follow-up 
with t-tests of group means. There was a significant difference in adherence levels between the 
two conditions at baseline, t(92) = -2.16, p = .03, with the TAU group (M = 80.81, SD = 26.41) 
reporting significantly greater levels of adherence than the eLifeSteps group (M = 67.20, SD = 
34.29). Results from the t-test at one-month follow-up failed to demonstrate a significant 
difference between conditions, t(93) = -0.87, p = .39. These results demonstrated a trend in 






in the TAU condition remained consistent between baseline and follow-up (see Table 6 for group 
means and standard deviations by time point).  
 
Primary Analyses Utilizing the Mean Imputation Method 
Treatment Self-Efficacy 
Immediate post-intervention scores on the measure of self-efficacy (HIV-ASES) for 
treatment adherence were calculated for all participants. For those who were missing data points 
at one-month follow-up, group means at baseline were calculated and imputed for that 
participant’s one-month follow-up data point. Time  Condition interaction effects in mixed 
model ANOVAs were examined and demonstrated a significant difference between the two 
conditions F(1, 87) = 6.91, p = .01, 
2
=.07 with participants in the eLifeSteps condition reporting 
higher scores of self-efficacy to adhere to their HIV treatment regimen (M =8.89, SD = 1.25)  
compared to the TAU participants (M =7.89, SD = 1.63) at 1-month follow-up.  Between-group 
differences in adherence were evaluated at baseline and one-month follow-up with t-tests of 
group means. Results for self-efficacy at baseline failed to reach significance, t(87) = 1.48, p = 
.14; however, there was a significant difference between groups at 1-month follow-up, t(87) = 
3.22, p = .002. This suggests that, on average, participants who completed the eLifeSteps 
intervention demonstrated an increase in belief to adhere to the prescribed HIV medication 
regimen between baseline assessment and 1-month follow-up, while participants in the TAU 







Adherence scores were calculated for all participants using self-reported 4-day recall 
data. For those who were missing data points at one-month follow-up, group means at baseline 
were calculated and imputed for that participant’s one-month follow-up data point. Time  
Condition interaction effects in mixed model ANOVAs were evaluated to examine differences in 
patterns of change in adherence over time and demonstrated a statistically significant difference 
between conditions F(1, 92) = 4.13, p=.045, 
2
=.04. Between-group differences in adherence 
were evaluated at baseline and one-month follow-up with t-tests of group means. There was a 
significant difference in adherence levels between the two conditions at baseline, t(92) = -2.16, p 
= .03. Results from the t-test at one-month follow-up failed to demonstrate a significant 
difference between conditions, t(93) = -0.82, p = .42. These results are consistent with the 
regression imputation and LOCF results.  
Primary Analyses Excluding Non-Completers 
Treatment Self-Efficacy 
The last observation carried forward, regression imputation, and mean imputation 
methods resulted in a sample size of ninety-five. Since excluding non-completers omits 
participants from the analyses, the sample size for the following analyses resulted in sixty-eight 
participants. Immediate post-intervention scores on the measure of self-efficacy (HIV-ASES) for 
treatment adherence were calculated for all participants who completed both baseline and follow-
up assessment points. Time  Condition interaction effects in mixed model ANOVAs were 
examined and demonstrated a significant difference between the two conditions F(1, 65) = 6.78, 
p = .01, 
2
=.09. Between-group differences in adherence were evaluated at baseline and 1-month 






groups at baseline, t(70) = 2.07, p = .04 Participants in the eLifeSteps condition reported higher 
scores of self-efficacy to adhere to their HIV treatment regimen compared to the TAU 
participants at baseline and 1-month follow-up (see Table 6 for means and standard deviations).   
Adherence 
Time  Condition interaction effects in mixed model ANOVAs were also evaluated to 
examine differences in patterns of change in adherence over time and failed to reach a 
statistically significant interaction F(1, 66) = 1.26, p = 0.27, 
2
=.02. Between-group differences 
in adherence were evaluated at baseline and 1-month follow-up with t-tests of group means. Both 
tests failed to reach significance at baseline, t(71) = -1.37, p = .18, and at 1-month follow-up 
t(67) = 0.01, p = .99. 
Conclusions from the Various Methods of Handling Missing Data 
Discrepancies in Outcomes by Method 
 Results from the analyses utilizing the mean imputation [F(1, 87) = 6.91, p = .01, 
2
=.07] 
and regression imputation [F(1, 87) = 4.70, p<.05, 
2
=.05] methods revealed significant 
differences between conditions in regards to HIV treatment self-efficacy (see Table 7). The last 
observation carried forward (LOCF) method, however, failed to reach significance, F(1, 87) = 
2.93, p = .09, 
2
=.03.  A similar pattern of results was identified in regards to the adherence 
variable. The mean imputation [F(1, 92) = 4.13, p=.045, 
2
=.04] and regression imputation [F(1, 
92) = 3.75, p=.056, 
2
=.04] methods revealed results that approached significance. The LOCF 









The LOCF method provides conservative results; however, it is problematic when 
participants drop-out of the study early in the trial and when responses are expected to change 
over time (Myers, 2000). Considering that this study only utilizes two data points (baseline and 
1-month follow-up) and change is expected to occur over time, use of the LOCF method likely 
underestimating the effect of the intervention. The LOCF approach has been a common method 
used in handling missing data in clinical trials for decades; however, recent literature supports 
that this method is not ideal (Mallinckrodt, et al., 2003; Kenward, M. & Molenberghs, 2009). 
Additionally, the mean imputation method may distort the distribution of the variable measured. 
With these consideration in mind, it was determined that the use of regression imputation would 







Table 6 Primary analyses excluding non-completers 
Primary Outcome 
Measure 
eLifeSteps TAU   
M SD M SD F p 
HIV Self-Efficacy     6.78 .012 
     Baseline 8.67 1.68 7.79 1.92   
     Follow-up 8.91 1.39 7.96 1.81   
Adherence     1.26 .27 
     Baseline 67.06 34.96 79.35 28.14   






Table 7 Primary outcomes as a function of analytical method 
Analytic Strategy Primary Outcome 
Measure 
eLifeSteps TAU   
M SD M SD F p 
Last Observation Carried Forward       
 HIV Self-Efficacy     2.93 .09 
      Baseline 8.46 1.77 7.88 1.90   
      Follow-up 8.60 1.59 8.00 1.82   
 Adherence     3.47 .07 
      Baseline 67.20 34.29 80.81 26.41   
      Follow-up 76.33 31.73 82.80 26.03   
Mean Imputation       
 HIV Self-Efficacy     6.91 .01 
      Baseline 8.46 1.77 7.88 1.90   
      Follow-up 8.90 1.25 7.89 1.63   
 Adherence     4.13 .045 
      Baseline 67.20 34.29 80.81 26.41   
      Follow-up 76.23 25.63 81.68 24.24   
Regression Imputation       
 HIV Self-Efficacy     4.70 .03 
      Baseline 8.46 1.77 7.88 1.90   
      Follow-up 8.77 1.34 7.96 1.67   
 Adherence     3.75 .056 
      Baseline 67.20 34.29 80.81 26.41   
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Module 1: Education and Introduction 
(Slide 1) Welcome to the Electronic Life Steps program. My name is Kasey and I will be 
guiding you through each step in the program. This program will give you tools to help 
fight against HIV and be healthier. We will focus on learning skills to help you take your 
medications as prescribed by your doctor. (click) 
(Slide 2) HIV medications help many people manage their HIV and live longer, healthier 
lives.  Unfortunately, these medications don’t work if you do not take them properly and 
for the long-term.  This program will teach you valuable skills that will help you 
incorporate your HIV medications into your daily life.  Throughout this program we will 
use the term (click) “medication adherence” to refer to how consistent you are with 
taking your HIV medications as prescribed by your doctor.  Adherence includes taking 
the correct doses of your medications every time you are supposed to take them. 
In order for your medications to work properly, you need to take your medications 
exactly as they are prescribed.  This can be challenging since taking HIV medications is a 
daily, lifelong treatment.  (click) Inaccurate use of your medications, or nonadherence, 
(click) includes taking drug holidays, (click) taking medications incorrectly, (click) when 
a person stops taking his or her medications, (click) using treatments or substances not 
prescribed by your doctor, (click) and not attending medical appointments.  All of these 
behaviors may result in severe consequences for your health and quality of life.  (click)  
(Slide 3) Only taking medications properly some of the time may result in the 
development of treatment resistant strands of HIV.  (click) This means that your body has 
become resistant to the medication you are taking and that medication will stop working.  
(click) This may result in an increase in your viral load and a decrease in your CD4 cell 
count and you will likely have to change to a different medication.  (click) The term 
“viral load” refers to the amount of HIV in your blood.  The higher the amount of HIV in 
your bloodstream, the more at risk you are at for having damage to your immune system.  
Your immune system fights germs and infections.  (click) The immune system is made 
up of white blood cells which are also called CD4 cells.  HIV destroys CD4 cells and 
causes the immune system to become weak and unable to fight off infections and germs.   
This can result in you getting infections that can cause serious illness or even death. 
In order for you to keep your CD4 count high and your immune system functioning 
properly; it is very important that you follow the directions your doctor gave you about 
when and how to take your HIV medications.  Medication adherence is a skill that you 
learn.  You will learn different skills in this program to help you maintain a high level of 
adherence to your HIV medications.  (click) 
It is important to understand that pill taking for HIV medications may be different from 
other pill-taking behaviors.  (click) With many conditions, such as headaches, the 
occurrence of symptoms serves as a reminder to take medication.  For instance, when you 
have a headache, you decide to take medication to get rid of the headache. The symptoms 






(click)  With HIV, medications are taken to prevent the occurrence of certain symptoms, 
but may cause side effects.  Throughout this session, we will develop reminders to take 
pills on schedule and learn how to deal with the side effects that you may experience. 
(click) 
(Slide 5) The purpose of this program is to help you effectively follow the medical 
regimen prescribed by your doctor. (click) This program will teach you skills to help you 
manage your HIV medications and (click) improve your ability to be consistent with 
taking your medications long-term. This is important for two reasons. First, making sure 
that you’re doing everything you can to manage your HIV is the best way to keep you 
physically healthy. Second, if you have a plan and the skills needed to put that plan into 
practice, you will feel less overwhelmed by your self-care regimen. In the following 
modules you will learn problem-solving strategies to help you overcome barriers that 
may cause you to not adhere to your medication regimen. As you go through the 
program, you will complete exercises in the workbook that was given to you before you 
began this program. 
(click) In your workbook, turn to page 1. You will see an exercise called “The Pros and 
Cons of Changing.”  Use this form to determine the benefits and the consequences of 
changing.  You will also think about the benefits and consequences of not changing. It is 
important to emphasize that there are definitely pros of not changing such as being used 
to the way things are now and not changing to be more comfortable and maybe easier in 
the short-term. The cons of not changing, however, can mean that you do not get a 
chance to see whether some of these strategies will actually make a difference and 
improve your quality of life.  Take some time now to think about the pros and cons of 
changing and write them down in each box. After you have completed the exercise click 
on the play button located at the bottom of the screen (click). 
(Next slide) Now, turn to page 2 of your workbook. Rate your level of motivation on a 
scale of 1-10, with 1 representing no motivation at all and 10 representing high 
motivation. Remember to click on the play button to continue to the next section. 
(Next slide) (click) Many people can feel overwhelmed when first confronted with the 
number of new things needed to manage a complicated medical regimen. Being able to 
manage your HIV doesn’t have anything to do with what kind of person you are. (click) 
It’s something that changes over time and depends on the skills and support you have to 
successfully carry out your regimen. (click) It can be a lot like learning to drive a car for 
the first time. First, you need to learn about all the steps and why they’re important: how 
to hold the wheel, how much pressure to apply to the pedals, when to check your mirrors, 
and so forth.  At first, each one of these steps requires a lot of concentration and effort. 
You have to specifically remember to do them, and make sure to focus your attention. 
After doing them repeatedly over time, they feel less and less like steps and more and 
more like automatic behaviors. As much as possible, we want to help you learn the skills 
necessary to manage your illness well enough so that you can incorporate them into your 






a car. (click) Learning the steps involved in managing your HIV and following through 
with them is the best way you can get to better health and quality of life. (click) 
Part of this process involves the use of problem-solving skills.  One part of problem 
solving involves defining the problem and breaking it down into steps. First, we are going 
to directly apply problem-solving to medication adherence. In problem-solving, the first 
thing needed is to define the problem and think about goals. So, that is where we will 
begin. 
 
Before we start, turn to page 3 in your workbook.  What thoughts do you have regarding 
adherence to your medical regimen? Write your thoughts down in the blanks provided.  
When you are finished remember to click the play button. (click) 
 
What are some things that may get in the way of adhering to your regimen? (click) 
When you look at your medications and supplies, what goes through your mind? (click) 
What are your top five reasons for staying adherent and taking care of your HIV? (click) 
 
Now, we are going to go through a checklist of problems that some people have with 
medical adherence. By completing the checklist, solving problems related to adherence, 
and continuing to practice, you can make successful adherence a part of your daily 
routine. (click) 
We will use a tool called AIM to solve some of your adherence-related problems. (click) 
The first step in AIM is to articulate, or think about, the particular adherence goal. (click) 
The second step is to identify barriers to reaching your goal. (click) The final step is to 
make a plan to overcome the barriers, as well as to develop a backup plan. 
Turn to page 4 of your workbook and use the Adherence Goals Worksheet provided to 
write down the self-care behaviors that are specific to you and your illness. Throughout 
the program, we will target these goals and develop plans for meeting them. Remember 







Module 2: Getting to Appointments 
“This is the first of the steps that involve problem-solving strategies and rehearsal 
techniques.  You will use these skills to help you identify ways that will help you get to 
your medical appointments.  We will be using the AIM problem-solving technique 
described in the previous module.  Please refer to page 5 in your workbook.  (Click) 
On page 5, write down your adherence goal regarding medical appointments on question 
number 1. (PAUSE)  How often do you have medical appointments? (PAUSE) Where are 
your appointments located? After you have completed this question, click the play button 
to continue. (click) 
Now identify potential barriers to making medical appointments and write them down on 
question number 2.  What might cause you to miss appointments? (PAUSE) Does your 
schedule conflict with scheduling appointments? (PAUSE) Do you live very far away? 
(PAUSE) What might be some additional barriers?  
An example of potential barriers may include having children and not being able to find 
child care the day that you have your appointment. Another barrier might be working 
during the hours when the clinic is open. (click) 
Now, make a plan and a back-up plan and write it down for question number 3.  How will 
you get to your appointments in case the weather is bad or you can’t go the way you 
usually go? (PAUSE) Is there public transportation nearby or does the clinic have a 
medical van that can pick you up or would it be better to call and reschedule? (PAUSE) 
How can you schedule your appointments and make sure you remember them?  (PAUSE)  
Develop a back-up plan in case problems come up.  For instance, you may choose to 
schedule appointments early in the morning or late in the afternoon, go during lunch 
hour, or you may choose to know the public transportation schedules in case your other 
transportation fails.” Here’s an example of a plan and back-up plan: I will schedule my 
appointments well in advance and arrange for child care. I will schedule appointments 
during my lunch hour at work so that I will be able to make the appointment.  My back-
up plan in case I do not have child care the day of my appointment is to take my kids to 
my friend, Suzy’s house who lives down the street from me and has volunteered to help if 











Module 3:  Communicating with Treatment Team 
“Communication with your medical provider can be a key component of treatment 
success. Having HIV is a sensitive issue and many people feel embarrassed about asking 
questions of their health-care providers.  Many patients have difficulty remembering 
questions to ask their provider, become nervous during medical visits, and forget 
information. This module will help you develop a plan for improving communication 
with your doctor or medical team.  We will be using the worksheet on page 6 to help 
develop the plan. (click) 
First, on question number 1, identify any questions or comments that you would like to 
ask or discuss with your medical provider.  During your next visit with your doctor, what 
questions do you want to ask about your symptoms, medications, side effects, or 
recommended self-care behaviors, such as questions about diet and exercise? (click) 
Second, what are some potential barriers to communication with your medical provider? 
Do you feel uncomfortable talking to your doctor? Do you feel that he or she is too busy 
to talk to you or do you tend to forget what you want to ask? What might cause you to not 
ask your doctor the questions that you have? (click) 
Now make a plan and back-up plan. How will you remember the questions that you want 
to ask your doctor? It may be helpful to write down your questions on an index card to 
bring to the medical visit.  There is an index card in the front pocket of your workbook 








Module 4: Coping with Side Effects 
“If you are taking medication to manage your illness, you are no doubt experiencing 
some side effects.  There are many potential solutions to side effects, but these solutions 
tend to vary across illnesses.  In this module you will identify which side effects are most 
distressful to you.  It is important that you always consult with your physician about ways 
to manage your side effects. Fortunately, in many cases, with adequate medication 
adherence, side effects decrease over time.  However, when side effects occur, some 
people do not strictly follow their medication schedule and decrease their level of 
adherence. This can result in developing treatment resistant strands of HIV and cause the 
disease to progress faster.  It is vital that you do not allow side effects to push you out of 
strictly adhering to your treatment regimen. (click) 
Using the worksheet on page 7, write down any problems with adherence that may 
emerge due to side effects. What kinds of side effects do you experience? (PAUSE) 
Which of your medications do you think are causing the side effects?  
Example: ‘I experience headaches, nausea, and muscle aches.’ (click) 
Identify potential barriers and write them next to question number 2. Have your side 
effects gotten in the way of taking your medication? (PAUSE) What have you done about 
the side effects so far? (PAUSE) Have you been able to talk to your doctor about these 
side effects? (click) 
Now make a plan and a back-up plan.  
Example: ‘I will talk to my doctor about these side effects to see what else can be done to 






Module 5: Obtaining Medications and Other Health-Related Products 
Having a continued access to your medications is important for treatment success.  If you 
have your medications mailed to your home, you need to remember to call the refills in at 
least 3 days early so you can be sure the medications arrive in time and you do not miss 
any doses.  
This module will help you to develop a plan for continued access to medications, 
including payment, selection of a pharmacy, and back-up plans. It is important for you to 
work with your health care provider to develop a plan for continued access to 
medications or other health-related products.  The plan should include information 
regarding payment options, pharmacy selection, back-up plans for transportation or other 
issues, and management of your interactions with the pharmacist. (click) 
Using the worksheet on page 8, write down the adherence goal of always having a 
sufficient supply of medications and needed supplies. Where do you get your medications 
and medical supplies? (PAUSE) How do you pay for your medications and medical 
supplies? (PAUSE) How do you get to your pharmacy? (PAUSE) Have you ever run out 
of your medications or medical supplies? (PAUSE) When do you ask for a medication 
refill from your pharmacy? (PAUSE) When do you ask for a prescription refill from your 
doctor? (click) 
Identify potential barriers.  What might cause you to run out of your medications or other 
needed medical supplies? (PAUSE) What might get in the way of getting to your 
pharmacy? (PAUSE) What might get in the way of getting another prescription from 
your doctor? (click) 
Now make a plan and a back-up plan.  How will you get to your pharmacy? (PAUSE) If 
there is bad weather, how will you get to your pharmacy? (PAUSE) Can you set up a 
medication mail-in so that your medications can be mailed to you directly? (PAUSE) 
How can you make sure that you do not run out of your medications? (PAUSE) How can 








Module 6:  Formulating a Daily Medication Schedule 
This module will help you devise ways of reminding yourself to take your medication. 
Complete the Medical Regimen Worksheet provided on page 9 of your workbook. A 
sample worksheet has been provided on page 10 for you to use as a model when filling 
out your own.  The goal of completing this worksheet is to develop a detailed map of an 
average day of pill-taking, specifying environmental and other cues for pill-taking 
throughout the day, such as taking your medicine after you brush your teeth.  The 
toothbrush is a cue in your environment to remind you to take you medications. 
It may be helpful to use this worksheet for each day of the week or a weekday and a 
weekend. When completing the Medical Regimen Worksheet, be sure to take into 
account the ideal times and conditions for taking medications, such as during an empty 
stomach or with food.” 
It is important that you consider variations in a “typical” day.  It is often times more 
challenging to remember to take medication on days when we do not have a routine, such 
as weekends, holidays, or vacations.” (click) 
Using the AIM technique and page 11 of your workbook, first, write down the adherence 
goal of remembering to take medications and follow your medical regimen. When do you 
take your medications? (PAUSE) How do you remember to take your medications?  
(click) 
Next, identify potential barriers.  When do you tend to forget to take your medications? 
(PAUSE) Identify specific times that are potential risks for missing doses such as 
weekends due to disruptions in routine.  (PAUSE) Do you usually take your medications 
when you are doing something else?  For instance, you may take your medication with 
your cup of coffee and toast in the morning or when you get home from work each day or 
during the nightly news. (PAUSE) What gets in the way of taking your medications 
regularly? (click) 
Now make a plan and back-up plan.  What activities can you do at the same time as you 
take your medication so that each time you do it, you will remember to take your 
medications too.  Examples include during breakfast or with an afternoon snack. When 
would be the best times to schedule taking your medications? (PAUSE) How can you be 
sure to follow what you need to with respect to adhering to your medication regimen? 
(PAUSE) What if you forget to take your medications? 
It’s important to know your schedule for each day of the week and when you will take 
your medicine.  Having a set time that you will take your medicine each day of the week 







Module 7: Storing Medications and Medical Supplies 
“Now that you know your daily schedule, it is important to address the issue of storing 
the medications when you are not at home. Some medications require safe and portable 
storage or refrigeration.  If this is the case with your medicines, we need to use problem-
solving skills to address this issue. Please turn to page 12 of your workbook. (click) 
“First, think about the adherence goal of properly storing your medications, even when 
you are not at home. You may wish to find private places to keep your medications to 
maintain confidentiality. If you leave home, do you take your medications with you if 
you know you will not be back in time for your dose? How do you carry your 
medications with you when you go out? Do you keep them in a pillbox or a bag? 
Remember to click the play button once you are ready to continue. (click) 
“Identify potential barriers.  Where do you keep your medications when you go out and 
bring then with you? (PAUSE) Do any of your medications need to be refrigerated? 
(PAUSE) What will you do about storing medications when you are away from home? 
(click) 
“Now make a plan and back-up plan. If your medications need to be refrigerated, what 
can you do instead of storing your medications in work or others’ refrigerators? Some 
people find that taking a refrigerated lunch bag with an ice pack is helpful.  
“Take a look at your dose times again and see if you can take your doses in such a way 
that you will not have to worry about keeping your medication cold. For medications that 
retain their potency for a number of hours, you may be able to time the doses so that 
storage in a refrigerator is not necessary. Would you be able to buy and use a small 
Ziplock bag or a pillbox for each dose of the day? That way you can mark each bag with 
the appropriate time you are supposed to take your medications and any other things you 
need to remember about them, like certain foods to eat or not eat with them and 
refrigeration information.  You may also consider keeping back-ups in your car trunk or 






Module 8: Cue-Control Strategies for Taking Medications 
 “In this module, you will learn strategies for remembering to take medications and for 
rehearsing adaptive thoughts of adherence each time you look at the cues.” (click) 
 “In your folder are round, colored adhesive stickers.  These stickers can be placed in or 
around your home or workplace as reminder cues. (click) 
After placing the stickers in specific places such as on your bathroom mirror or on your 
computer at work, take one of the same stickers and place it on a note card. (click twice)  
Write on the note card a particular issue you want to be reminded of when you see the 
stickers elsewhere.  For example, you may write, ‘I am taking my medicine so I can be 
healthy for my loved ones.’ Post the note card in a place where you will see it often, so 
that whenever you see the sticker in your home or at your job, you can remember what it 
stands for. This provides a link between the adaptive thoughts we identified in the first 
module and the dots in your environment.” 
“Now we are going to use the AIM technique to solve problems related to using these 
cue-control strategies.  We will be using the problem solving worksheet 8.1 found on 
page 13 of your workbook.  The first step is to write down the adherence goal of using 
strategies for improving your motivation to take medications and for remembering to take 
them. How do you usually help remind yourself to take medications? (PAUSE)  What do 
you think about when you know it is time to take your medications?  (LONG PAUSE).  
Once you have completed this question click the play button to continue. 
Next, identify potential barriers. What things do you think may keep you from using 
dots? (PAUSE) Do you think the dots would be helpful reminders to take your 
medications? (LONG PAUSE) 
Now, make a plan and a back-up plan.  Where can you place each dot so that you can see 
it at each dosing time? For example, you may place a dot near a doorknob inside the 
house, near the lock outside the door, bathroom mirror, work computer, phone receiver, 
or any other helpful places.  What other things do you think you can use to help you 
remember your medications? (PAUSE) For some people linking trips to the bathroom 
when you wake up and before going to bed help to serve as reminders.  Other people may 
use pill boxes with built-in timer alarms, a wake-up call service, clocks or timers that 
chime on the hour or half-hour, or use computers or their cell phones to sound alarms at 






Module 9: Handling Slips 
“This module will help you prepare to recover from missing doses or any other slip-up 
you may experience from your medical routine. If a lapse occurs, the best choice is to 
return to your adherence program as soon as possible instead of acting on hopeless 
thoughts and giving up.  Identifying what led to the lapse can provide you with important 
information that can help solidify your coping skills and avoid future lapses.  Lapses are 
normal and not a big problem. They only become a big problem when they lead to 
relapse and cause you to give up on your self-care regimen. 
“Although you may expect that you will continually improve as your treatment 
progresses, this may not be the case. Everyone experiences ups and downs and good days 
and bad days. (click) 
“This graph shows the difference between what most people who participate in this 
program believe their progress should look like and the reality of how progress usually 
happens. At times during your involvement with this program, you may experience a 
worsening of your symptoms or difficulty using the skills you’ve learned effectively. 
Instead of losing hope, look at these times as opportunities to gather information about 
what contributed to the negative change and use this knowledge to better prepare yourself 
in the future.  Remember, lapses are completely normal. Over the long run, successfully 
dealing with short-term lapses will help you to maintain the positive results of your 
treatment. (click) 
“Now, using page 14 in your workbook, think about the adherence goal of understanding 
that making a change takes time and practice-slips can happen. How would you feel if 
you didn’t take your medications one day, either because you forgot or because you were 
sick and didn’t feel like it? What would you do if that happened? (click) 
“Next, identify potential barriers. What kinds of thoughts do you think may keep you 
from restarting your medical regimen if you have a slip? (click) 
“Make a plan and back-up plan. What can you do to pick yourself up and start where you 
left off before you had a slip? When a slip occurs, try to avoid all-or-nothing thinking. 
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